Finex Pulse • Market Signal Briefing

Details	Saved	Published	Title	Source	Tickers
	2026-03-05 22:07 6d ago	2026-03-05 16:54 6d ago	Ripple's RLUSD Stablecoin Expands DeFi Reach With New Morpho Vault	cryptonews	MORPHO RLUSD XRP
TLDR: RLUSD’s market cap has more than doubled in six months, per Sentora’s announcement this week. The Sentora vault on Morpho accepts five collateral types: cbBTC, weETH, wstETH, sUSDe, SyrupUSDC. Morpho runs as a permissionless lending network, letting curators set their own risk parameters. The RLUSD vault is live on Ethereum, with Sentora acting as the designated vault curator. Ripple’s RLUSD stablecoin now has a dedicated lending vault on Morpho. Sentora, a DeFi vault curator, launched the product this week. The vault allows users to supply RLUSD and earn yield through curated lending markets. It marks another step in pushing RLUSD deeper into on-chain financial infrastructure. Sentora Builds Curated Lending Market Around RLUSD on Morpho RLUSD has grown steadily since its launch. Its market cap has more than doubled over the past six months, according to Sentora. Much of that growth ties directly to expanding its presence across DeFi protocols and multichain deployments. The new Morpho vault adds a structured lending venue to that effort. Users deposit RLUSD into the vault. Borrowers can then access that liquidity by posting approved collateral through Morpho’s lending markets. Sentora controls the risk parameters of the vault. That includes selecting which collateral assets qualify and setting the associated lending terms. The vault currently accepts five collateral types: cbBTC, weETH, wstETH, sUSDe, and SyrupUSDC. This spread gives borrowers flexibility while maintaining a diversified collateral base for the vault. Morpho’s Permissionless Design Draws Institutional-Grade Activity Morpho operates as a permissionless, non-custodial lending network. Developers and institutions can build customized lending markets directly on top of its protocol. Rather than relying on shared liquidity pools, the protocol supports curated vaults with configurable risk settings. That design has driven fast growth. Morpho has become one of the more active lending infrastructures in DeFi, according to Sentora’s announcement. For RLUSD, the structure offers a clean fit. Sentora manages risk. Morpho handles the underlying infrastructure. Suppliers access yield. Borrowers access stablecoin liquidity. The vault is now live on Ethereum. Sentora published the contract address and a direct link to the Morpho app interface in its announcement posted on X. Morpho also flagged the launch on its own X account, describing it as new utility for RLUSD and calling attention to Sentora’s role as curator. The move signals continued momentum for RLUSD beyond its original issuance role. Stablecoins increasingly function as active settlement assets within DeFi, not just passive stores of value. The Sentora vault adds a concrete use case to that trend.
	2026-03-05 22:07 6d ago	2026-03-05 17:00 6d ago	Solana seeing rising interest, but is it enough to boost SOL?	cryptonews	SOL
Journalist Posted: March 6, 2026 Amid rising downside risk, Solana [SOL] has struggled to hold above $90 since breaching it. As the broader market signaled recovery, the altcoin jumped to a local high of $94 before a slight pullback. As of this writing, SOL traded at $90.76, up 5.07% on the daily charts, adding to its 3% weekly gains. Amid this thin bearish structure, institutional investors have been squeezing, attempting to absorb the pressure. Institutions step in to buy Solana’s dip Solana recently struggled to make any gains because large entities, both whales and institutions, stepped back. Some of these investors capitulated and increased spending, while others sat on the sidelines preserving capital. However, sentiment among these two groups has shifted significantly over the past three weeks. For starters, Solana Spot ETFs have recorded significant and sustained capital inflows, recording net inflows for three consecutive days. Source: Sosovalue Since recording net outflow in February, SOL ETFs have only recorded inflows. In fact, on the 4th of March, Net Inflow climbed to $19 million, the second-highest inflow since early January. Such massive inflows showed renewed interest in SOL assets among institutional investors, a key driver of the sustained price rally. Stablecoin transactions hit $650 billion While markets and Solana struggled throughout February, the month proved a breakout season for stablecoins. According to the Grayscale report, on-chain activity for Solana’s stablecoin surged to a record high. Stablecoin transaction volume on Solana climbed to a high of $650 billion, surpassing the record from October 2025 by more than 2x. This was the largest volume among all other chains in February, reflecting Solana’s rising dominance. Source: Grayscale These transactions were backed by over 5.3 million addresses, according to Artemis data. Recently, stablecoins have become major drivers for blockchain adoption, and the rising activity on Solana shows it is positioned for competition. Even more importantly, sustained network usage reflects the demand for the native token, and a continued rise could positively impact SOL. Is the demand adequate to boost SOL? While SOL has recently struggled to keep an upward momentum, the return of institutional investors has strengthened the market structure. Looking at the bias ratio, the altcoin holds above both short- and long-term deviations, indicating a gradual shift in momentum. Thus, the market has shown signs of a potential recovery from the February slip. Source: SosoValue The fact that Bias24 is higher shows that long-term recovery momentum is forming. At the same time, the Awesome Oscillator showed bears losing strength with the momentum shifting bullish. Together, these indicators signaled a potential trend reversal if the momentum holds. Thus, if the demand witnessed recently sustains, SOL is likely to successfully retest $94 and eye a move above $100. However, if market liquidity continues to shrink as investors step back, SOL will continue trading between $80 and $91. Final Summary Transaction volume for Solana stablecoins hit a record high of $650 billion, surpassing all other major chains. SOL’s momentum is gradually flipping bullish amid increased capital inflows into Solana Spot ETFs.
	2026-03-05 22:07 6d ago	2026-03-05 17:00 6d ago	Bitcoin Consolidates Near Key Support Band — $77,000 Holds The Key To The Next Move	cryptonews	BTC
Bitcoin is consolidating near a crucial support band, with $77,000 emerging as the key level to watch. A breakout above it could signal bullish momentum and a trend reversal, while failure to hold may keep Bitcoin in a corrective phase or push it lower. Bitcoin Re-Approaches Critical High-Timeframe Support After 0.786 Fibonacci Deviation Crypto analyst Luca highlighted that Bitcoin recently dipped below the high-timeframe support range marked in purple, briefly deviating toward the 0.786 Fibonacci point of interest around $65,900. Following that move, the price is now approaching the previously lost high-timeframe support zone, which coincides with the early April 2025 bottoming structure. This region also overlaps with the 3-day Bull Market Support Band, an area that has served as a strong reversal point several times over the past few months. Luca explained that this confluence of technical levels is the reason he has not yet reduced his hedge positions. Instead, he prefers to remain cautious until the market provides clearer confirmation of strength. According to Luca, such confirmation would likely come from Bitcoin reclaiming the lost support range or breaking above the Bull Market Support Band. Source: Chart from Luca on X Until that happens, the analyst warns that the current approach to this zone could still result in a rejection, meaning the move might represent a temporary bounce rather than a confirmed recovery. Luca also emphasized that traders should focus more on protecting capital rather than chasing profits at this stage. Only once clear strength appears, and the probability shifts toward a sustained upside continuation, would it make sense to adopt a more aggressive bullish stance. $77,000 Emerges As The Critical Confirmation Level For BTC According to Luca, the key confirmation level he is watching right now sits around $77,000. A decisive breakout above that level would signal stronger market momentum. Thus, Luca plans to gradually scale out of his hedge positions and rotate that capital back into his spot holdings, anticipating a more sustainable move to the upside. Luca also noted that attempting to squeeze out an extra 10–15% gain at current levels may not be the best risk decision. Instead of aggressively chasing short-term profits, he prefers to wait for a clear confirmation that the market structure is shifting in favor of the bulls. He added that the potential upside could be significantly larger if Bitcoin successfully reclaims the $77,000 level. However, exiting hedge positions too early could expose traders to the risk of a bullish fakeout, where the price briefly moves higher before resuming its downward trend. Because of that possibility, Luca maintains a cautious stance until stronger confirmation appears. BTC trading at $73,444 on the 1D chart \| Source: BTCUSDT on Tradingview.com Featured image from Pixabay, chart from Tradingview.com
	2026-03-05 21:06 6d ago	2026-03-05 16:01 6d ago	Moody's Ratings Upgrades Equinix's Senior Unsecured Rating to Baa1 with a Stable Outlook	stocknewsapi	EQIX
, /PRNewswire/ -- Equinix, Inc. (Nasdaq: EQIX), the world's digital infrastructure company®, announced that Moody's Ratings ("Moody's") has upgraded Equinix, Inc.'s senior unsecured ratings from Baa2 to Baa1. According to Moody's, the upgrade reflects the stable outlook of the company's established position in the global digital infrastructure market, the strong demand for data center capacity, and the expectation that credit metrics will remain strong. Additional credit strengths highlighted by Moody's include Equinix's geographic scale, customer diversity, excellent liquidity and continued growth in share of owned assets in its portfolio, which now account for 70% of recurring revenue as of Q4 2025. "We are pleased to have received Moody's upgrade of our senior unsecured rating to Baa1," said Keith Taylor, Chief Financial Officer, Equinix. "This is a strong recognition of Equinix's financial discipline and the sustained demand for our global digital infrastructure portfolio. Also, it reflects our consistent capital management approach and proven ability to access global capital markets, as we continue to execute on our growth strategy." About Equinix Equinix, Inc. (Nasdaq: EQIX) shortens the path to boundless connectivity anywhere in the world. Its digital infrastructure, data center footprint and interconnected ecosystems empower innovations that enhance our work, life and planet. Equinix connects economies, countries, organizations and communities, delivering seamless digital experiences and cutting-edge AI—quickly, efficiently and everywhere. Forward-Looking Statements This press release contains forward-looking statements that involve risks and uncertainties. Actual results may differ materially from expectations discussed in such forward-looking statements. Factors that might cause such differences include, but are not limited to, risks to our business and operating results related to the current inflationary environment; foreign currency exchange rate fluctuations; stock price fluctuations; increased costs to procure power and the general volatility in the global energy market; the challenges of building and operating IBX® and xScale® data centers, including those related to sourcing suitable power and land, and any supply chain constraints or increased costs of supplies; the challenges of developing, deploying and delivering Equinix products and solutions; unanticipated costs or difficulties relating to the integration of companies we have acquired or will acquire into Equinix; a failure to receive significant revenues from customers in recently built out or acquired data centers; failure to complete any financing arrangements contemplated from time to time; competition from existing and new competitors; the ability to generate sufficient cash flow or otherwise obtain funds to repay new or outstanding indebtedness; the loss or decline in business from our key customers; risks related to our taxation as a REIT; risks related to regulatory inquiries or litigation; and other risks described from time to time in Equinix filings with the Securities and Exchange Commission. In particular, see recent and upcoming Equinix quarterly and annual reports filed with the Securities and Exchange Commission, copies of which are available upon request from Equinix. Equinix does not assume any obligation to update the forward-looking information contained in this press release. SOURCE Equinix, Inc.
	2026-03-05 21:06 6d ago	2026-03-05 16:01 6d ago	ArriVent BioPharma Reports Full Year 2025 Financial Results	stocknewsapi	AVBP
March 05, 2026 16:01 ET \| Source: ArriVent BioPharma, Inc. Topline global pivotal Phase 3 data for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC expected mid-2026Global pivotal Phase 3 first-line PACC mutant NSCLC study for firmonertinib enrollment underwayADC pipeline advancing with first ADC program, ARR-217, in Phase 1 clinical development Cash and investments of $312.8 million as of December 31, 2025 expected to fund operations into 3Q 2027 NEWTOWN SQUARE, Pa., March 05, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today reported financial results for the year ended December 31, 2025, and highlighted recent Company progress. “We are advancing firmonertinib toward potential registration, supported by two pivotal programs targeting uncommon EGFR mutations in non-small cell lung cancer (NSCLC), a high unmet need with limited treatment options,” said Bing Yao, CEO of ArriVent. “Our robust clinical data, including CNS activity, underscores the potential of firmonertinib to become a chemotherapy-free standard of care. We look forward to topline pivotal data for firmonertinib monotherapy in frontline EGFR exon 20 insertion mutant NSCLC expected in mid-2026. This is an event driven study, so we plan to continue sharpening our timeline as we look forward to sharing our data.” Dr. Yao continued, “Our antibody-drug conjugate (ADC) portfolio is also gaining momentum, led by ARR-217, a CDH17-targeted ADC currently in an ongoing Phase 1 trial, with best-in-class potential in gastrointestinal cancers. We expect additional ADC candidates to advance toward the clinic, broadening our pipeline beyond lung cancer into multiple additional solid tumor indications. Backed by a strong balance sheet and a projected cash runway into 3Q 2027, we are well positioned to deliver on our near-term catalysts.” Recent and Full Year 2025 Highlights Firmonertinib Dosed first in patient pivotal ALPACCA study. In December 2025, ArriVent announced dosing of the first patient in the global pivotal Phase 3 ALPACCA study evaluating firmonertinib monotherapy for first-line treatment of epidermal growth factor receptor (EGFR) PACC mutant non-small cell lung cancer (NSCLC) (NCT07185997).Positive final data in EGFR PACC mutant NSCLC. In September 2025, ArriVent presented positive final proof-of-concept data from the randomized global Phase 1b FURTHER trial cohort of first-line firmonertinib monotherapy in patients with NSCLC harboring EGFR PACC mutations at the 2025 World Conference on Lung Cancer (WCLC) (NCT05364073). Firmonertinib demonstrated clinically meaningful progression free survival, central nervous system (CNS) complete responses, and a manageable safety profile consistent with previous trials. We believe this to be the first clinical dataset testing an EGFR inhibitor in a prospectively defined population of EGFR PACC mutant NSCLC.Completed enrollment for pivotal FURVENT trial. During the first quarter of 2025, we completed enrollment in the global pivotal Phase 3 FURVENT study of firmonertinib monotherapy in first-line NSCLC EGFR exon 20 insertion mutations (NCT05607550). Firmonertinib, an oral, highly brain-penetrant, and broadly active mutation-selective EGFR inhibitor, received Food and Drug Administration (FDA) Breakthrough Therapy Designation in this patient population.Received National Medical Products Administration (NMPA) approval in China in second-line EGFR exon 20 insertion mutations. In February 2026, our partner Shanghai Allist Pharmaceutical Technology Co., Ltd., received NMPA approval for firmonertinib for adults with locally advanced or metastatic NSCLC who have progressed on or after prior platinum-based chemotherapy or who are intolerant to platinum-based chemotherapy and who have been tested for the presence of EGFR exon 20 insertion mutations. Pipeline Clinical advancement of ADC lead ARR-217 (MRG007). Ongoing Phase 1 dose escalation for ARR-217, a CDH17 targeted ADC, in gastrointestinal malignancies in partnership with Lepu Biopharma Co., Ltd. ArriVent also received FDA IND clearance for ARR-217 and dosed its first patient in March 2026. Upcoming Milestones Firmonertinib pivotal EGFR exon 20 insertions data. Top-line firmonertinib monotherapy data from the global pivotal FURVENT Phase 3 (NCT05607550) study for first-line EGFR exon 20 insertions mutant NSCLC is projected to be in mid-2026.IND filing for ARR-002. U.S. IND filing for first-in-class ADC program planned for first half 2026. Plan to present preclinical data at an upcoming conference.Complete Phase 1 dose escalation for ARR-217. Plan to complete Phase 1 dose escalation and enter into dose optimization for ARR-217, a CDH17 targeting ADC program, in the second half of 2026. 2025 Financial Results As of December 31, 2025, the Company had cash and investments of $312.8 million, which is expected to fund operations into 3Q 2027. Net cash used in operations was $160.6 million and $70.2 million for the years ended December 31, 2025 and 2024, respectively.Research and development expenses were $153.4 million and $79.0 million for the years ended December 31, 2025 and 2024, respectively. The research and development expenses in 2025 include a one-time upfront payment to Lepu Biopharma Co., Ltd.General and administrative expenses were $24.2 million and $15.3 million for the years ended December 31, 2025 and 2024, respectively.Net loss was $166.3 million and $80.5 million for the years ended December 31, 2025 and 2024, respectively. About ArriVent ArriVent is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. ArriVent seeks to utilize its team’s deep drug development experience to maximize the potential of its lead development candidate, firmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody drug conjugates, through approval and commercialization. About Firmonertinib Firmonertinib is an oral, highly brain-penetrant, and broadly active mutation-selective epidermal growth factor receptor (EGFR) inhibitor active against both classical and uncommon EGFR mutations, including PACC and exon 20 insertion mutations. In March 2021, firmonertinib was approved in China for first-line advanced non-small-cell lung cancer (NSCLC) with EGFR exon 19 deletion or L858R mutations and for patients with previously treated locally advanced or metastatic NSCLC with EGFR T790M mutation, otherwise known as EGFR classical mutations. Firmonertinib was granted U.S. Food and Drug Administration (FDA) Breakthrough Therapy Designation for the treatment of patients with previously untreated locally advanced or metastatic non-squamous NSCLC with EGFR exon 20 insertion mutations. Firmonertinib was also granted U.S. FDA Orphan Drug Designation for the treatment of NSCLC with EGFR mutations or human epidermal growth factor receptor 2 (HER2) mutations or HER4 mutations. Firmonertinib is currently being studied in a global Phase 3 trial for first-line NSCLC patients with EGFR exon 20 insertion mutations (FURVENT; NCT05607550) and in a global Phase 3 study in first line NSCLC patients with EGFR PACC mutations (ALPACCA; NCT07185997). About EGFR mutant NSCLC Globally, lung cancer is the leading cause of cancer-related deaths among men and women. NSCLC is the predominant subtype of lung cancer, accounting for approximately 85% of all cases. Mutational activation of the EGFR is a frequent and early event in the development of NSCLC. EGFR mutations are divided into classical and uncommon. EGFR exon 20 insertion mutations are a group of uncommon EGFR mutations and constitute approximately 9% of all EGFR mutations. PACC mutations are another group of uncommon EGFR mutations and represent approximately 12% of all EGFR mutations. Patients with NSCLC whose tumors harbor uncommon EGFR mutations have significantly lower life expectancy with available therapies and represent an area of unmet medical need. About EGFR PACC mutations P-loop and αC-helix compressing (PACC) EGFR mutations are a distinct set of approximately 70 mostly missense activating mutations within the kinase domain of EGFR. They are similar to exon 20 insertion mutations in narrowing the drug binding pocket to affect tyrosine kinase inhibitor activity. PACC mutations are diagnosed through commercially available NGS and most PCR tests. Patients with PACC mutations have limited treatment options, and there is no broadly utilized standard of care treatment for first-line PACC mutant patients. About FURVENT FURVENT is a global, pivotal 3 arm Phase 3 clinical trial of firmonertinib in first-line non-squamous locally advanced or metastatic NSCLC patients with exon 20 insertion mutations being conducted jointly with our partner Allist (NCT05607550). The FURVENT clinical trial is designed to assess the safety and efficacy of firmonertinib administered at either 160 mg or 240 mg, once-daily with each dose being compared to platinum-based chemotherapy with pemetrexed, the current first-line standard of care. The primary endpoint of this study is PFS by BICR per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. Secondary endpoints in patients with brain metastases at baseline include brain-specific CNS overall response rate (CNS-ORR) and CNS-PFS by modified RECIST (mRECIST). The study enrolled 398 patients globally, including from sites in the United States, Europe and certain Asian countries including Japan and China. About ALPACCA ALPACCA is a global, pivotal 2 arm Phase 3 clinical trial of firmonertinib in first-line non-squamous locally advanced or metastatic NSCLC patients with PACC mutations being conducted jointly with our partner Allist (NCT07185997). The ALPACCA trial is evaluating firmonertinib 240 mg once daily versus investigator’s choice of osimertinib or afatinib in first-line patients with EGFR PACC mutant NSCLC. The 240 mg dose of firmonertinib was selected for pivotal development based on compelling data showing a 16-month median PFS and a confirmed 68% ORR by BICR in the FURTHER trial (NCT05364073). The primary endpoints of this study are ORR and PFS by BICR per RECIST. Forward-Looking Statements This press release includes certain disclosures that contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 about us and our industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations or financial condition, business strategy and plans, cash runway, estimates of our addressable market, activity of firmonertinib compared to available therapies, anticipated clinical milestones, the timing of, and results of, top-line pivotal Phase 3 data for firmonertinib in previously untreated NSCLC patients whose tumors contain EGFR exon 20 insertion mutations, the timing of our planned enrollment of the global pivotal Phase 3 study of firmonertinib in previously untreated NSCLC patients whose tumors contain EGFR PACC mutations, the advancement of the Phase 1 study for ARR-217 in gastrointestinal tumors and the timing of presentation of data from that study, the timing of U.S. IND filing for ARR-002, and objectives of management for future operations, are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or the negative of these words or other similar terms or expressions. Forward-looking statements are based on ArriVent’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties that are described more fully in the section titled “Risk Factors” in our annual report on Form 10-K for the fiscal year ended December 31, 2025, to be filed with the Securities and Exchange Commission on March 5, 2026 and our other filings with the Securities and Exchange Commission. Forward-looking statements contained in this press release are made as of this date, and ArriVent undertakes no duty to update such information except as required under applicable law. ARRIVENT BIOPHARMA, INC. BALANCE SHEETS(in thousands, except share and per share data)(Unaudited) December 31, 2025 2024 Assets Current assets: Cash and cash equivalents $45,540 $74,293 Short-term investments 267,281 144,570 Prepaid expenses and other current assets 20,076 8,116 Total current assets 332,897 226,979 Long-term investments — 47,683 Right of use assets – operating leases 13 154 Deferred offering costs 69 — Other assets 190 126 Total assets $333,169 $274,942 Liabilities and Stockholders’ Equity Current liabilities: Accounts payable $5,934 $3,782 Accrued expenses 19,997 13,330 Operating lease liabilities 14 162 Total current liabilities 25,945 17,274 Operating lease liabilities, net of current amount — 14 Total liabilities 25,945 17,288 Stockholders’ equity: Preferred stock $0.0001 par value, 10,000,000 shares authorized; no shares issued and outstanding — — Common stock $0.0001 par value, 200,000,000 shares authorized; 42,452,251 and 33,706,765 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively 4 3 Additional paid-in capital 711,847 496,195 Accumulated deficit (404,641) (238,333)Accumulated other comprehensive income (loss) 14 (211)Total stockholders’ equity 307,224 257,654 Total liabilities and stockholders’ equity $333,169 $274,942 ARRIVENT BIOPHARMA, INC. STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS(in thousands, except share and per share data)(Unaudited) Year Ended December 31, 2025 2024 Operating expenses: Research and development $153,351 $79,004 General and administrative 24,183 15,304 Total operating expenses 177,534 94,308 Operating loss (177,534) (94,308)Interest and investment income 11,226 13,820 Net loss (166,308) (80,488)Unrealized gain (loss) on marketable securities 225 (211)Total other comprehensive gain (loss) 225 (211)Total comprehensive loss $(166,083) $(80,699) Share information: Net loss per share attributable to common stockholders, basic and diluted $(4.32) $(2.56)Weighted-average shares of common stock outstanding, basic and diluted 38,462,600 31,469,328 Contact: Joyce Allaire LifeSci Advisors, LLC [email protected]
	2026-03-05 21:06 6d ago	2026-03-05 16:01 6d ago	Galapagos Appoints Tania Philipp as Chief Human Resources Officer	stocknewsapi	GLPG
Seasoned Life Sciences Executive Joins Galapagos with Strong Track Record in Change Management Mechelen, Belgium; March 5, 2026, 22:01 CET — Galapagos NV (Euronext & NASDAQ: GLPG) today announced the appointment of Tania Philipp as Chief Human Resources Officer (CHRO), effective March 4, 2026. Ms. Philipp will also join the Management Committee. She succeeds Annelies Missotten, who will remain with the company through June 30, 2026, to ensure a smooth transition. Ms. Philipp brings nearly three decades of experience as an executive-level human resources leader supporting the vision, mission and objectives of life sciences companies. Most recently, she served as an Executive Human Resources Consultant at Vor Bio, following several years as Chief People Officer and Vice President, Head of People, supporting the organization through key phases of development. Prior to that, she held HR leadership roles including Vice President, Human Resources at Tango Therapeutics, and senior HR roles at Bavarian Nordic and other life science organizations. Ms. Philipp holds an M.A. in Psychology from the University of the Pacific and attended Hollins University. “We are delighted to welcome Tania to Galapagos,” said Henry Gosebruch, CEO of Galapagos. “Tania brings a proven ability to build strong cultures within early-stage life sciences organizations undergoing transformation. She will play a critical role as we build a high-performing, purpose-driven culture at Galapagos focused on brining meaningful medicines to patients.” Gosebruch continued: “I also want to thank Annelies for her outstanding leadership and contributions during her time at Galapagos. I am grateful that we will continue to benefit from her experience and leadership over the next several months as we continue to execute our transformation.” “I am excited to join Galapagos at this important moment in the Company’s evolution,” said Ms. Philipp. “I look forward to partnering with the leadership team to further strengthen our culture and ensure we are well positioned to execute our strategy and deliver meaningful value for patients and shareholders.” About Galapagos Galapagos is a biotechnology company built to bring meaningful medicines to patients with serious diseases in therapeutic areas of unmet need. The Company combines world-class deal making expertise with capital to identify, acquire, and advance promising opportunities that have the potential to drive value for patients and shareholders. Applying a modality-agnostic asset selection approach and operational flexibility, Galapagos prioritizes oncology and immunology & inflammation programs with clear clinical proof-of-concept in emerging areas. For more information, visit www.glpg.com or follow us on LinkedIn or X. For further information, contact Galapagos: Investor Relations Glenn Schulman +1 412 522 6239 [email protected] Media Media Katie Morris +1 952 288 6821 [email protected] Visit us at www.glpg.com or follow us on LinkedIn or X. Forward-looking statements This press release may include forward-looking statements, all of which involve certain risks and uncertainties. These statements are often, but not always, made through the use of words or phrases such as “will,” “long-term,” and “forward,” and any similar expressions. These statements include, but are not limited to, statements regarding the announced leadership transition and changes in our Management Committee and key personnel; Mr. Philipp’s expected responsibilities and potential contributions to the company, and the company’s strategic formation. Any forward-looking statements in this press release are based on our management’s current expectations and beliefs and are not guarantees of future performance. Forward-looking statements may involve unknown and known risks, uncertainties, and other factors which might cause our actual results, performance, or achievements to be materially different from any historic or future results, performance, or achievements expressed or implied by such statements. These risks, uncertainties, and other factors include, without limitation, the risk that Galapagos will encounter challenges retaining or attracting talent, that our leadership transition may be disruptive to our business operations, and risks related to our ability to effectively transfer knowledge during this period of transition. A further list and description of these risks, uncertainties, and other factors can be found in our filings and reports with the Securities and Exchange Commission (SEC), including in our most recent annual report on Form 20‐F filed with the SEC, as supplemented and/or modified by any other filings and reports that we have made or will make with the SEC in the future. Given these risks and uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. In addition, even if our results, performance, or achievements are consistent with such forward-looking statements, they may not be predictive of results, performance, or achievements in future periods. These forward-looking statements speak only as of the date of publication of this press release. We expressly disclaim any obligation to update any forward-looking statements in this press release, unless required by law or regulation. Galapagos Appoints Tania Philipp as Chief Human Resources Officer
	2026-03-05 21:06 6d ago	2026-03-05 16:01 6d ago	FormFactor to Host Upcoming Investor Day	stocknewsapi	FORM
March 05, 2026 16:01 ET \| Source: FormFactor, Inc. LIVERMORE, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- FormFactor, Inc. (NASDAQ: FORM), a leading provider of essential test and measurement technologies enabling next-generation semiconductor innovation, today announced that it will host its Investor Day at the Nasdaq MarketSite in New York City. Location: Nasdaq MarketSite at 151 W 43rd Street, 10th Floor Date & Time: May 11th, 2026 from 10:00 am to 1:00 pm Eastern Time During the event, members of FormFactor’s executive leadership team will provide an in‑depth review of FormFactor’s strategic priorities, long‑term growth opportunities, operational initiatives, and financial targets. A live webcast and accompanying presentation materials will be available on the Investor Relations section of FormFactor’s website at www.formfactor.com. A replay of the webcast will also be accessible following the event. If you are an institutional investor or a financial analyst interested in attending this event in person, please contact [email protected]. About FormFactor: FormFactor, Inc. (NASDAQ: FORM), is a leading provider of essential test and measurement technologies along the full IC life cycle - from characterization, modeling, reliability, and design de-bug to qualification and production test. Semiconductor companies rely upon FormFactor's products and services to accelerate profitability by optimizing device performance and advancing yield knowledge. The Company serves customers through its network of facilities in Asia, Europe, and North America. For more information, visit the Company's website at www.formfactor.com. Investor Contact: Stan Finkelstein Investor Relations (925) 290-4273 [email protected] Source: FormFactor, Inc. FORM-F
	2026-03-05 21:06 6d ago	2026-03-05 16:01 6d ago	aTyr Pharma Announces Fourth Quarter and Full Year 2025 Results and Provides Corporate Update	stocknewsapi	ATYR
Company scheduled to meet with the FDA in mid-April 2026 to review the results of the Phase 3 EFZO-FIT™ study and determine the path forward for efzofitimod in pulmonary sarcoidosis. Phase 2 EFZO-CONNECT™ study of efzofitimod in systemic sclerosis-related interstitial lung disease (SSc-ILD) on track to complete enrollment in the first half of 2026.
	2026-03-05 21:06 6d ago	2026-03-05 16:01 6d ago	OptimizeRx Reports Strong Fourth Quarter and Full Year 2025 Financial Results	stocknewsapi	OPRX
- Q4 revenue of $32.2 million- Q4 gross profit increased 9% year-over-year to $24.1 million- Q4 net income and adjusted EBITDA hit records at $5.0 million and $12.0 million, respectively- Updating 2026 revenue guidance to $109-$114 million and adjusted EBITDA guidance to $21-$25 million- Paid off an incremental $2 million in principal from term loan during Q4- OptimizeRx's Board authorizes a $10 million share repurchase program WALTHAM, Mass., March 05, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced results for the fourth quarter and full year ended December 31, 2025. Financial Highlights Revenue in the fourth quarter of 2025 remained consistent at $32.2 million when compared to $32.3 million in the same period of 2024. Full year revenue for 2025 came in at $109.4 million, a 19% increase, when compared to $92.1 million in the same year-ago period.Gross profit in the fourth quarter of 2025 increased 9% year-over-year to $24.1 million from $22.0 million in the same period of 2024. Gross profit for the full year of 2025 was $73.6 million an increase from $59.4 million in the same year-ago period.GAAP net income in the fourth quarter of 2025 totaled $5.0 million, or $0.26 per diluted share, compared to net loss of $(0.1) million, or $0.00 per diluted share, in the same period of 2024. GAAP net income for the full year of 2025 totaled $5.1 million, or $0.27 per diluted share, compared to net loss of $(20.1) million, or $(1.10) per diluted share, in the same year-ago period.Non-GAAP net income in the fourth quarter of 2025 totaled $9.9 million, or $0.51 per diluted share, compared to $5.5 million, or $0.30 per diluted share in the same period of 2024. Non-GAAP net income in the full year of 2025 came in at $19.9 million, or $1.05 per diluted share, compared to $6.2 million, or $0.33 per diluted share, in the same year-ago period. (see Non-GAAP Measures below).Adjusted EBITDA for the fourth quarter of 2025 increased to $12.0 million compared to $8.8 million in the same period of 2024. Adjusted EBITDA for the full year of 2025 came in at $24.3 million compared to $11.7 million in the same year-ago period. (see Non-GAAP Measures below).Cash and cash equivalents was $23.4 million as of December 31, 2025 as compared to $13.4 million as of December 31, 2024Net cash provided by operating activities was $18.7 million for the year ended December 31, 2025 as compared to $4.9 million in the same period of 2024. Stephen L. Silvestro, OptimizeRx CEO commented, “We delivered a strong fourth quarter, exceeding both consensus and internal expectations, with revenue of $32.2 million and adjusted EBITDA of $12.0 million. For the full year, revenue reached a record $109.4 million and adjusted EBITDA totaled $24.3 million, reflecting more than 20% margin and nearly $19 million in operating cash flow. Importantly, one year ago, we set a goal to become a Rule of 40 company and we have, in 2025, achieved this benchmark demonstrating the strength of our profitable growth model and the durability of our platform. We continue to be focused on becoming a sustainable Rule of 40 company over the next few years. “We are beginning to see increased market volatility, driven in part by uncertainty surrounding Most Favored Nation (MFN) pricing. In response, we believe some customers are taking a more measured approach to discretionary spending and contract duration. While this dynamic may create some near-term headwinds, we continue to see solid engagement across our network and remain confident in the underlying demand trends supporting our business. “Against that backdrop, OptimizeRx continues to play a mission-critical role for life sciences companies by enhancing brand visibility, reducing script abandonment, improving interoperability between disparate point-of-care platforms, and supporting the growing shift toward complex specialty medications. In addition, we believe advancements in AI will enable customers to reallocate marketing dollars from content creation toward reach and execution—areas where we provide differentiated value with significant ROIs, further strengthening our position over time.” For the Year Ended December 31, Key Performance Indicators (KPIs)*2025 2024 (in thousands, except percentages) Average revenue per top 20 pharmaceutical manufacturers$2,838 $2,976 Percent of total revenue attributable to top 20 pharmaceutical manufacturers 52% 65% Net revenue retention 116% 121% Revenue per average full-time employee$839 $701 Financial Outlook The Company is also updating its fiscal year 2026 guidance at this time and is expecting revenue to be between $109 million and $114 million with Adjusted EBITDA to be between $21 million and $25 million. Share Repurchase Program OptimizeRx’s board of directors has authorized a share repurchase program for up to $10 million of the Company’s outstanding common stock. Under this new program, share repurchases may be made from time to time depending on market conditions, share price, share availability and other factors at the Company’s discretion. This share repurchase authorization is effective March 12, 2026 and expires on the earlier of March 15, 2027, or when the repurchase of $10 million shares has been reached. The Company’s repurchase of shares will take place in open market transactions or privately negotiated transactions in accordance with applicable securities and other laws, including the Securities Exchange Act of 1934. The Company intends to finance the purchase using its available cash and cash equivalents. The Company’s board of directors may modify, suspend, extend or terminate the share repurchase program at any time. Conference Call, Webcast, and Webcast Replay Information Date:Thursday, March 5, 2026Time:4:30 p.m. Eastern Time (1:30 p.m. Pacific Time)Toll Free:1-844-825-9789International:1-412-317-5180Conference ID: 10206362Call Me:https://callme.viavid.com/?$Y2FsbG1lPXRydWUmcGFzc2NvZGU9JmluZm89Y29tcGFueSZyPXRydWUmYj0xNg==Webcast:https://viavid.webcasts.com/starthere.jsp?ei=1750927&tp_key=099094fd29Call Me Passcode:6586380Webcast Replay:The archived webcast will be on the investor relations section of the OptimizeRx website Invitation In an effort to increase relations with institutional investors, OptimizeRx management has dedicated time to hosting individual meetings with portfolio managers and analysts. If you are interested in scheduling a meeting with OptimizeRx management, please contact: [email protected] or [email protected]. Non-GAAP Measures In addition to the financial measures prepared in accordance with generally accepted accounting principles (GAAP), this earnings release also contains non-GAAP financial measures. The reasons why we believe these measures provide useful information to investors and, for historical periods, a reconciliation of these measures to the most directly comparable GAAP measures are included in the supplemental tables that follow. Although the Company provides guidance for Adjusted EBITDA, a non-GAAP financial measure, it is not able to provide guidance to the most directly comparable GAAP measure. Reconciliations for forward-looking figures would require unreasonable effort at this time because of the uncertainty and variability of the nature and amount of certain components of various necessary GAAP components, including, for example, those related to compensation, acquisition expenses, other income, amortization or others that may arise during the year, and the Company’s management believes such reconciliations would imply a degree of precision that would be confusing or misleading to investors. For the same reasons, the Company is unable to address the probable significance of the unavailable information. **Definition of Key Performance Indicators Top 20 pharmaceutical manufacturers: We have updated the definition of “top 20 pharmaceutical manufacturers” in our key performance indicators to be based upon Fierce Pharma’s most updated list of “The top 20 pharma companies by 2024 revenue”. We previously used “The top 20 pharma companies by 2023 revenue”. As a result of this change, prior periods have been restated for comparative purposes. Net revenue retention: Net revenue retention is a comparison of revenue generated from all clients in the previous period to total revenue generated from the same clients in the following year (i.e., excludes new client relationships for the most recent year). Revenue per average full-time employee: We define revenue per average full-time employee (FTE) as total revenue over the last 12 months (LTM) divided by the average number of employees over the LTM, which is calculated by taking our total number of FTEs at the end of the prior year period by our total FTE headcount at the end of the most recent period. About OptimizeRx OptimizeRx is a leading healthcare technology company that’s redefining how life science brands connect with patients and healthcare providers. Our platform combines innovative artificial intelligence (AI)-driven tools like the Dynamic Audience Activation Platform (DAAP) and Micro-Neighborhood Targeting (MNT) to deliver timely, relevant, and hyper-local engagement. By bridging the gap between HCP and DTC strategies, we empower brands to create synchronized marketing solutions that drive faster treatment decisions and improved patient outcomes. Our commitment to privacy-safe, patient-centric technology ensures that every interaction is designed to make a meaningful impact, delivering life-changing therapies to the right patients at the right time. Headquartered in Waltham, Massachusetts, OptimizeRx partners with some of the world’s leading pharmaceutical and life sciences companies to transform the healthcare landscape and create a healthier future for all. For more information, follow the Company on X, LinkedIn or visit www.optimizerx.com. Important Cautions Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipates”, “believes”, “estimates”, “expects”, “forecasts”, “intends”, “plans”, “projects”, “targets”, “designed”, “could”, “may”, “should”, “will” or other similar words and expressions are intended to identify these forward-looking statements. All statements that reflect the Company’s expectations, assumptions, projections, beliefs or opinions about the future, other than statements of historical fact, are forward-looking statements, including, without limitation, statements relating to the Company’s future performance, expected revenues, expected Adjusted EBITDA, plans to grow shareholder value creation, plans to continue the Company’s growth and transformation, plans to position the Company to become a sustained “Rule of 40” company, increased market volatility, engagement across the Company’s network, improving interoperability between disparate point-of-care platforms, growing shift toward complex specialty medications, advancements in AI, plans to pay down debt at an accelerated rate, momentum extending into 2026, setting the stage for sustained strength in 2026 and beyond, the timing and amount of repurchases of our common stock and other statements relating to future performance, plans, and expectations. These forward-looking statements are based on the Company’s current expectations and involve assumptions regarding the Company’s business, the economy, and other future conditions that may never materialize or may prove to be incorrect. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted, or quantified. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties including, but not limited to, the effect of government regulation, seasonal trends, dependence on a concentrated group of customers, cybersecurity incidents that could disrupt operations, the ability to keep pace with growing and evolving technology, the ability to maintain contracts with electronic prescription platforms and electronic health records networks, competition, and other factors discussed in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, its subsequent Quarterly Reports on Form 10-Q, and in other filings the Company has made and may make with the Securities and Exchange Commission in the future. One should not place undue reliance on these forward-looking statements, which speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as may be required by law. OptimizeRx Contact Andy D’Silva, Chief Business Officer [email protected] Investor Relations Contact Steven Halper LifeSci Advisors, LLC [email protected] OPTIMIZERX CORPORATION CONSOLIDATED BALANCE SHEETS (in thousands, except share and per share data) December 31, 2025 2024 ASSETS Current assets Cash and cash equivalents$23,365 $13,380 Accounts receivable, net of allowance for credit losses of $260 and $335 at December 31, 2025 and 2024, respectively 37,752 38,212 Taxes receivable 752 — Prepaid expenses and other 2,846 2,379 Total current assets 64,715 53,971 Property and equipment, net 106 150 Other assets Goodwill 70,869 70,869 Patent rights, net 4,586 5,517 Technology assets, net 6,870 8,180 Tradename and customer relationships, net 29,340 31,819 Operating lease right-of-use assets 404 366 Security deposits and other assets 28 296 Total other assets 112,097 117,047 TOTAL ASSETS$176,918 $171,168 LIABILITIES AND STOCKHOLDERS’ EQUITY Current liabilities Current portion of long-term debt$4,255 $2,000 Accounts payable 1,636 2,156 Accrued expenses 11,591 8,486 Revenue share payable 3,086 5,053 Taxes payable — 318 Current portion of lease liabilities 193 168 Deferred revenue 503 473 Total current liabilities 21,264 18,654 Non-current liabilities Long-term debt, net 21,421 30,816 Lease liabilities, net of current portion 234 209 Deferred tax liabilities, net 5,705 4,491 Total liabilities 48,624 54,170 Commitments and contingencies Stockholders’ equity Preferred stock, $0.001 par value, 10,000,000 shares authorized, none issued and outstanding at December 31, 2025 and 2024, respectively — — Common stock, $0.001 par value, 166,666,667 shares authorized, 20,500,986 and 20,194,697 shares issued at December 31, 2025 and 2024, respectively 20 20 Treasury stock, $0.001 par value,1,741,397 shares purchased at December 31, 2025 and 2024 (2) (2) Additional paid-in-capital 207,512 201,348 Accumulated deficit (79,236) (84,368) Total stockholders’ equity$128,294 $116,998 TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY$176,918 $171,168 OPTIMIZERX CORPORATION CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, except share and per share data) For the Three Months Ended December 31, For the Year Ended December 31, 2025 2024 2025 2024 Net revenue$32,239 $32,317 $109,429 $92,127 Cost of revenues, exclusive of depreciation and amortization presented separately below 8,139 10,293 35,834 32,749 Gross profit 24,100 22,024 73,595 59,378 Operating expenses Stock-based compensation 1,960 2,937 6,962 11,467 Impairment charges 368 — 368 7,489 Depreciation and amortization 1,078 1,094 4,327 4,329 Other general and administrative expenses 12,125 14,358 50,245 49,799 Total operating expenses 15,531 18,389 61,902 73,084 Income (loss) from operations 8,569 3,635 11,693 (13,706) Other income (expense) Interest expense (1,241) (1,563) (5,294) (6,160) Other income 59 41 198 152 Interest income 84 96 353 329 Total other expenses, net (1,098) (1,426) (4,743) (5,679) Income (loss) before provision for income taxes 7,471 2,209 6,950 (19,385) Income tax expense (2,451) (2,286) (1,818) (725) Net income (loss)$5,020 $(77) $5,132 $(20,110) Weighted average number of shares outstanding – basic 18,661,212 18,418,519 18,555,343 18,292,935 Weighted average number of shares outstanding – diluted 19,381,024 18,418,519 18,998,463 18,292,935 Income (loss) per share – basic$0.27 $— $0.28 $(1.10) Income (loss) per share – diluted$0.26 $— $0.27 $(1.10) OPTIMIZERX CORPORATION CONSOLIDATED STATEMENTS OF CASH FLOWS (in thousands) For the Year Ended December 31, 2025 2024 OPERATING ACTIVITIES: Net income (loss)$5,132 $(20,110) Adjustments to reconcile net income (loss) to net cash provided by operating activities: Depreciation and amortization 4,327 4,329 Impairment charges 368 7,489 Bad debt expense — 208 Stock-based compensation 6,962 11,467 Amortization of debt issuance costs 1,110 835 Change in: Accounts receivable 460 (2,168) Prepaid expenses and other assets (467) 811 Accounts payable (520) (72) Revenue share payable (1,967) (453) Accrued expenses and other liabilities 3,374 1,053 Operating lease liabilities 12 — Taxes receivable and payable (1,070) — Deferred tax liabilities 1,214 1,449 Deferred loan fees (250) (250) Deferred revenue 30 301 NET CASH PROVIDED BY OPERATING ACTIVITIES 18,715 4,889 INVESTING ACTIVITIES: Purchases of property and equipment (58) (112) Capitalized software development costs 126 (338) NET CASH PROVIDED BY (USED IN) INVESTING ACTIVITIES 68 (450) FINANCING ACTIVITIES: Repayment of long-term debt (8,000) (4,000) Cash paid for employee withholding taxes related to the vesting of restricted stock units (1,150) (911) Proceeds from exercise of stock options, net of cash paid for withholding taxes 352 — NET CASH USED IN FINANCING ACTIVITIES (8,798) (4,911) NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS 9,985 (472) CASH AND CASH EQUIVALENTS – BEGINNING OF PERIOD 13,380 13,852 CASH AND CASH EQUIVALENTS – END OF PERIOD$23,365 $13,380 SUPPLEMENTAL CASH FLOW INFORMATION: Cash paid for interest$4,184 $6,203 Cash paid for income taxes$1,760 $161 OPTIMIZERX CORPORATION RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES (in thousands, except share and per share data, unaudited) This earnings release includes certain financial measures not derived in accordance with generally accepted accounting principles (GAAP). These non-GAAP financial measures are measures of performance not defined by accounting principles generally accepted in the United States and should be considered in addition to, not in lieu of, GAAP reported measures. Additionally, these non-GAAP measures may not be comparable to similarly titled measures reported by other companies. However, management believes that presenting certain non-GAAP financial measures provides additional information to facilitate comparison of the Company's historical operating results and trends in its underlying operating results and provides transparency on how the Company evaluates its business. Management uses these non-GAAP financial measures in making financial, operating and planning decisions and in evaluating the Company's performance. Management believes that financial information excluding certain items that are not considered to reflect the Company’s ongoing operating results, such as those listed below, improves the comparability of year-to-year results. Consequently, management believes that investors may be able to better understand the Company’s operating results excluding these items. Non-GAAP financial measures may reflect adjustments for items such as asset impairment charges, amortization, stock-based compensation, acquisition expenses, severance tied to executive departures and reduction in force initiatives, shareholder activist related fees, CEO search fees, other income, as well as other items that management believes are not related to the Company’s ongoing performance. For the Three Months Ended December 31, For the Twelve Months Ended December 31, 2025 2024 2025 2024 Net income (loss)$5,020 $(77) $5,132 $(20,110) Deferred income taxes 153 1,215 153 Depreciation and amortization 1,078 1,094 4,327 4,329 Stock-based compensation 1,960 2,937 6,962 11,467 Impairment charges 368 — 368 7,489 Severance charges — 1,183 275 1,908 Shareholder activist related fees — — 451 — CEO search fees — — 225 — Other income (59) (40) (198) (152) Amortization of debt issuance costs 325 288 1,110 835 Acquisition expense — — — 243 Non-GAAP net income 5,538 19,867 6,162 Non-GAAP net income per share Diluted$0.51 $0.30 $1.05 $0.33 Weighted average shares outstanding: Diluted 19,381,024 18,464,605 18,998,463 18,583,936 For the Three Months Ended December 31, For the Twelve Months Ended December 31, 2025 2024 2025 2024 Net income (loss)$5,020 $(77) $5,132 $(20,110) Depreciation and amortization 1,078 1,094 4,327 4,329 Stock-based compensation 1,960 2,937 6,962 11,467 Impairment charges 368 — 368 7,489 Severance charges — 1,183 275 1,908 Acquisition expense — — — 243 Shareholder activist related fees — — 451 — CEO search fees — — 225 — Other income (59) (40) (198) (152) Interest expense (income), net 1,157 1,466 4,941 5,831 Income tax expense 2,451 2,286 1,818 725 Adjusted EBITDA 11,975 8,849 24,301 11,730
	2026-03-05 21:06 6d ago	2026-03-05 16:01 6d ago	Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026	stocknewsapi	CRVS
Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT
	2026-03-05 21:06 6d ago	2026-03-05 16:01 6d ago	Research Frontiers Reports Fourth Quarter and Year-End 2025 Financial Results and Will Host a Conference Call at 4:30p.m. Today	stocknewsapi	REFR
WOODBURY, N.Y., March 05, 2026 (GLOBE NEWSWIRE) -- Research Frontiers Inc. (Nasdaq: REFR) announced its financial results for its fourth quarter and full year 2025. Management will host a conference call today at 4:30 p.m. Eastern Time to discuss its financial and operating results as well as recent developments. •Who: Joseph M. Harary, President & CEO •Date/Time: Thursday, March 5, 2026, 4:30 PM ET •Dial-in Information:1-888-334-5785 •Conference Link: https://join.broaddata.com/?id=research-frontiers •Replay: Available on Friday, March 6, 2026 for 90 days at https://smartglass-ir.com/ Key Highlights for 2025: 1. First North American OEM Serial Production – Cadillac Celestiq SPD-SmartGlass entered serial production and customer deliveries on General Motors’ Cadillac Celestiq, marking the first North American OEM production program for SPD-SmartGlass technology. The Cadillac Celestiq program represents a significant validation milestone and establishes a platform for potential expansion into additional, higher-volume vehicle models. 2. Ferrari Program Transition and Royalty Recognition During 2025, the Ferrari Purosangue SPD-SmartGlass program transitioned from one European licensed supplier to another. Production levels resulted in minimum annual royalty thresholds exceeded during the third and fourth quarters of 2025. 3. Architectural Retrofit Market Entry At GlassBuild America 2025, the Company and its partners introduced a new SPD-SmartGlass retrofit system for the architectural market enabling conversion of existing glazing without full window replacement in homes, apartment buildings, and commercial office and government spaces. This development expands the addressable architectural market beyond new construction into retrofit projects and represents the first scalable pathway for installation into the large installed base of existing buildings. 4. SPD Film Advancements The Company and its licensees made significant progress on new types of SPD film designed to enhance optical uniformity, aesthetic integration and manufacturing efficiency. These advancements strengthen SPD’s competitive positioning, especially in the premium automotive and architectural applications. 5. Expanded Automotive Surface-Area Integration SPD-SmartGlass continued to be incorporated into concept and evaluation vehicles by global OEMs demonstrating broader glazing applications beyond traditional sunroof installations. The Mercedes Vision V concept integrated SPD across approximately 75% of vehicle glazing, highlighting the potential for materially larger surface-area adoption in future vehicle platforms. 6. Aerospace Production and Certification Strength SPD electronically dimmable windows continued flying across more than 40 aircraft models spanning commercial, business and specialty aviation segments, including HondaJet, Textron Beechcraft King Air, Daher TBM 960, Epic E1000, Airbus ACJ TwoTwenty and select Boeing 737 configurations. SPD remains the only commercially available light-control smart window technology known to the Company to have received FAA Supplemental Type Certification (STC) for retrofit programs, reinforcing its differentiated regulatory position and long-standing aviation track record and making SPD-Smart Electronically DimmableWindows (EDWs) uniquely suited for the aftermarket. 7. Increased Industry Visibility and Leadership The Company expanded its presence at major global automotive, aerospace and architectural forums. At the Automotive Glazing Summit in Detroit, the Company’s CEO served as Chairman and keynote speaker, reinforcing SPD’s growing recognition within OEM engineering and glazing leadership communities. 8. Financial Results, Liquidity and Capital Resources For the year ended December 31, 2025, revenue was approximately $1.12 million and net loss was approximately $2.05 million. During the year, revenue recognition was negatively impacted by the restructuring or bankruptcy of two licensees, which affected timing of royalty flows. The Company ended the year debt-free with approximately $0.7 million in cash and approximately $0.9 million in working capital. Subsequent to year-end, the Company bolstered its balance sheet by raising $1.1 million in a private placement to accredited investors, including members of a director’s family and the Company’s licensee responsible for the architectural retrofit application, further strengthening liquidity entering 2026. Joseph M. Harary, President and CEO of Research Frontiers noted: “2025 marked a meaningful inflection point for SPD-SmartGlass. We achieved our first North American OEM serial production program with Cadillac Celestiq, successfully transitioned and normalized Ferrari royalty recognition, introduced a scalable architectural retrofit solution, and advanced next-generation black SPD film technology. Since our last conference call, we have also begun work with several new automotive OEMs in Europe, expanded programs with existing OEMs into higher-volume vehicle models, and initiated specialty automotive and other applications beyond traditional sunroof configurations. While commercialization timing remains dependent on our licensees and their customers, we believe the breadth of ongoing evaluations, expanding surface-area integration, and entry into new application categories position SPD-SmartGlass for broader production deployment and long-term royalty growth. We believe the foundation now in place across automotive, aerospace and architectural markets creates increasing strategic opportunities and operating leverage as programs mature and move toward higher-volume implementation.” For more details, please see the Company’s Quarterly Report on Form 10-K which was filed today with the SEC, the contents of which are incorporated by reference herein. About Research Frontiers Research Frontiers (Nasdaq: REFR) is a publicly traded technology company and the developer of patented SPD-Smart light-control film technology which allows users to instantly, precisely and uniformly control the shading of glass or plastic products, either manually or automatically. Research Frontiers has licensed its smart glass technology to numerous companies that include well known chemical, material science and glass companies. Products using Research Frontiers’ smart glass technology are being used in tens of thousands of cars, aircraft, yachts, trains, homes, offices, museums and other buildings. For more information, please visit our website at www.SmartGlass.com, and on Facebook, Twitter, LinkedIn and YouTube. Note: From time to time Research Frontiers may issue forward-looking statements which involve risks and uncertainties. This press release contains forward-looking statements. Actual results, especially those reliant on activities by third parties, could differ and are not guaranteed. Any forward-looking statements should be considered accordingly. “SPD-Smart” and “SPD-SmartGlass” are trademarks of Research Frontiers Inc. CONTACT: Joseph M. Harary President and CEO Research Frontiers Inc. +1-516-364-1902 [email protected] RESEARCH FRONTIERS INCORPORATED Consolidated Balance Sheets December 31, 2025 and 2024 Assets December 31, 2025 December 31, 2024 Current assets: Cash and cash equivalents $664,299 $1,994,186 Royalties receivable, net of reserves of $1,384,850 and $1,253,450 in 2025 and 2024, respectively 408,666 658,213 Prepaid expenses and other current assets 70,969 93,490 Total current assets 1,143,934 2,745,889 Fixed assets, net 3,393 15,052 Operating lease ROU assets 1,048,352 1,222,640 Deposits and other assets 56,066 56,066 Total assets $2,251,745 $4,039,647 Liabilities and Shareholders’ Equity Current liabilities: Current portion of operating lease liability $146,043 $129,875 Accounts payable 132,666 85,825 Accrued expenses 19,168 53,327 Total current liabilities 297,877 269,027 Operating lease liability, net of current portion 1,020,242 1,166,285 Total liabilities 1,318,119 1,435,312 Shareholders’ equity: Common stock, par value $0.0001 per share; authorized 100,000,000 shares, issued and outstanding 33,648,221 in 2025 and 2024, respectively 3,365 3,365 Additional paid-in capital 128,552,068 128,177,193 Accumulated deficit (127,621,807) (125,576,223)Total shareholders’ equity 933,626 2,604,335 Total liabilities and shareholders’ equity $2,251,745 $4,039,647 See accompanying notes to consolidated financial statements. RESEARCH FRONTIERS INCORPORATED Consolidated Statements of Operations Years ended December 31, 2025 and 2024 2025 2024 Fee income $1,121,248 $1,335,531 Operating expenses 2,644,684 2,207,397 Research and development 608,732 570,007 Total expenses 3,253,416 2,777,404 Operating loss (2,132,168) (1,441,873) Net investment income 39,227 95,339 Other income 47,357 35,152 Net loss $(2,045,584) $(1,311,382) Basic and diluted net loss per common share $(0.06) $(0.04) Weighted average number of common shares outstanding 33,648,221 33,520,904 See accompanying notes to consolidated financial statements. RESEARCH FRONTIERS INCORPORATED Consolidated Statements of Shareholders’ Equity Years ended December 31, 2025 and 2024 Common Stock Additional Paid-in Accumulated Shares Amount Capital Deficit Total Balance, December 31, 2023 33,509,287 $3,351 $127,779,221 $(124,264,841) $3,517,731 Exercise of options 8,500 1 8,669 - 8,670 Share-based compensation - - 89,316 - 89,316 Issuance of common stock and warrants 130,434 13 299,987 - 300,000 Net loss - - - (1,311,382) (1,311,382)Balance, December 31, 2024 33,648,221 3,365 128,177,193 (125,576,223) 2,604,335 Share-based compensation - - 374,875 - 374,875 Net loss - - - (2,045,584) (2,045,584)Balance, December 31, 2025 33,648,221 $3,365 $128,552,068 $(127,621,807) $933,626 See accompanying notes to consolidated financial statements. RESEARCH FRONTIERS INCORPORATED Consolidated Statements of Cash Flows Years ended December 31, 2025 and 2024 2025 2024 Cash flows from operating activities: Net loss $(2,045,584) $(1,311,382)Adjustments to reconcile net loss to net cash used in operating activities: Depreciation and amortization 12,386 26,169 Share-based compensation 374,875 89,316 Credit loss expense 154,253 25,001 ROU asset amortization 174,288 237,394 Change in assets and liabilities: Royalty receivables 95,294 320,190 Prepaid expenses and other assets 22,521 3,294 Accounts payable and accrued expenses 12,681 74,080 Operating lease liability (129,875) (252,881)Net cash used in operating activities (1,329,161) (788,819) Cash flows from investing activities: Purchases of fixed assets (726) (1,623)Net cash used in investing activities (726) (1,623) Cash flows from financing activities: Net proceeds from exercise of options - 8,670 Proceeds from issuance of common stock and warrants - 300,000 Net cash provided by financing activities - 308,670 Net decrease in cash and cash equivalents (1,329,887) (481,772) Cash and cash equivalents, at beginning of year 1,994,186 2,475,958 Cash and cash equivalents, at end of year $664,299 $1,994,186 Supplemental disclosure of noncash items: Operating lease assets obtained for operating lease liabilities $- $1,281,319 See accompanying notes to consolidated financial statements.
	2026-03-05 21:06 6d ago	2026-03-05 16:01 6d ago	Gevo Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update	stocknewsapi	GEVO
ENGLEWOOD, Colo., March 05, 2026 (GLOBE NEWSWIRE) -- Gevo, Inc. (NASDAQ: GEVO) (“Gevo”, the “Company”, “we”, “us” or “our”), a leader in renewable fuels and chemicals as well as carbon management, today announced financial results for the fourth quarter and full year ended December 31, 2025 and provided an update on operating performance, cash flow, and progress across its carbon management and synthetic aviation fuel (“SAF”) growth platform. A quarterly earnings presentation of the financial results will also be posted to the Company's website at https://investors.gevo.com/news-events/events-presentations.
	2026-03-05 21:06 6d ago	2026-03-05 16:01 6d ago	CareDx Announces VANTx™, an AI‑Powered Clinical Data & Analytics Platform Built on CareDx's Proprietary, Large-Scale, Longitudinal Solid Organ Transplant Datasets	stocknewsapi	CDNA
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare solutions for transplant patients and caregivers, today announced the launch of VANTx™, an AI‑powered, cloud‑native clinical data and analytics platform designed to transform complex transplant data into insights that support clinical research and real‑world.
	2026-03-05 21:06 6d ago	2026-03-05 16:01 6d ago	Law Offices of Frank R. Cruz Encourages Apollo Global Management, Inc. (APO) Shareholders To Inquire About Securities Fraud Class Action	stocknewsapi	APO
LOS ANGELES--(BUSINESS WIRE)--Law Offices of Frank R. Cruz Encourages Apollo Global Management, Inc. (APO) Shareholders To Inquire About Securities Fraud Class Action.
	2026-03-05 21:06 6d ago	2026-03-05 16:01 6d ago	Trump trust bought up to $1.25M in Netflix debt during bidding war for Warner Bros. Discovery: filings	stocknewsapi	NFLX
President Trump’s trust bought as much as $1.25 million worth of Netflix bonds in January as the streamer was in a heated bidding war with Paramount Skydance for Warner Bros. Discovery, according to government filings released this week. The president bought $500,000 to $1 million worth of debt on Jan. 2 and made another purchase worth $100,000 to $250,000 on Jan. 20, according to the documents, which were posted online Wednesday by the US Office of Government Ethics. The two new transactions added to the $500,000 to $1 million in Netflix bonds the president purchased in December, just after the streaming giant announced its initial bid for Warner Bros. Discovery. President Trump’s trust bought as much as $1.25 million worth of Netflix bonds in January, according to government filings. REUTERS The president bought at least $500,000 worth of Warner Bros. stock in December, though the company’s stock did not appear in his January filing. Last week, Netflix CEO Ted Sarandos failed to convince skeptical Trump administration officials to approve his proposed takeover of WBD in spite of antitrust concerns – and the deal quickly fell apart from there, The Post reported. Netflix failed to hike its own offer to match David Ellison-led Paramount Skydance’s $111 billion deal and bowed out of the competition – making room for the Ellison family to acquire a behemoth media empire including CNN, CBS, HBO, Paramount and Warner Bros. After months of declines, Netflix stock has spiked about 17% since then. The White House has said that Trump’s assets are in a trust run by his children and managed by financial advisors, so there are no conflicts of interest. “President Trump only acts in the best interests of the American public – which is why they overwhelmingly re-elected him to this office, despite years of lies and false accusations against him and his businesses from the fake news media,” White House spokesperson Anna Kelly told The Post in a statement. Paramount Skydance CEO David Ellison vowed to maintain CNN’s “editorial independence.” REUTERS Netflix CEO Ted Sarandos failed to win over White House officials last week, The Post reported. Getty Images Trump also acquired bonds from companies like SiriusXM, General Motors, Occidental Petroleum, Victoria’s Secret, Macy’s, Carnival, Boeing and Wells Fargo, according to the filings. According to his most recent full-year financial disclosure, the president held a five-figure amount of Netflix stock in 2024. The document also showed Trump receiving a $333.31 residual check from Warner Bros. for his cameo appearances in “Two Weeks Notice,” “Suddenly Susan” and “The Fresh Prince of Bel-Air.” Warner Bros. Discovery CEO David Zaslav at the season three premiere of “The White Lotus” in February. Chris Pizzello/Invision/AP The president said last year that he would not be involved in the Warner Bros. deal’s review. Trump has long blasted CNN’s coverage of him as “dishonest,” and in December, he called for any deal involving WBD to hand the news channel over to new owners. David Ellison – whose billionaire father Larry Ellison is the founder of Oracle and a close Trump ally – assured Trump administration officials that he would make sweeping changes to CNN if he bought Warner Bros., the Wall Street Journal reported in December. “Larry Ellison is great and his son David is great,” Trump told reporters in October. “They’re friends of mine. They’re big supporters of mine, and they’ll do the right thing.” David Ellison pledged Thursday to maintain CNN’s “editorial independence” if the deal secures regulatory approvals, as staffers at the lefty cable network are reportedly panicking over a possible shift in editorial direction.
	2026-03-05 21:06 6d ago	2026-03-05 16:01 6d ago	D-Wave (QBTS) CEO on Earnings, Quantum Computing Profits & Acquisitions	stocknewsapi	QBTS
Dr. Alan Baratz, CEO of D-Wave (QBTS), talks about what he calls a "great year" for the company in 2025, and the profitability path the latest earnings paves. He notes 2026 sales of D-Wave's quantum computing products already outpaced all of last year.
	2026-03-05 21:06 6d ago	2026-03-05 16:02 6d ago	Aeroméxico February 2026 Traffic Results	stocknewsapi	AERO
March 05, 2026 16:02 ET \| Source: Grupo Aeroméxico, S.A.B. de C.V. MEXICO CITY, March 05, 2026 (GLOBE NEWSWIRE) -- Grupo Aeroméxico S.A.B. de C.V. (NYSE: AERO & BMV: AERO) (“Aeroméxico”) reports its February 2026 operational results: Grupo Aeroméxico transported 1 million and 744 thousand passengers in February 2026, a 1.2% year-over-year decrease. International passengers increased by 2.7%, while domestic passengers decreased by 3.0%.Aeroméxico's total capacity, measured in available seat miles (ASMs), decreased by 2.2% year-over-year. International ASMs decreased by 1.6%, while domestic capacity decreased by 3.6% year-over-year. Demand, measured in passenger miles (RPMs), increased by 1.2% year-over-year. International demand increased by 3.0%, while domestic demand decreased by 2.6%, both figures compared to February 2025. Aeroméxico’s February 2026 load factor was 82.7%, a 2.8 p.p. increase as compared to February 2025. International load factor increased by 3.7 p.p., and domestic load factor increased by 0.9 p.p. Andrés Conesa, Chief Executive Officer stated: “The continued recovery, particularly across international markets, is clearly reflected in our February traffic performance. Strong load factors validate the resilience and structural flexibility embedded in our operating model, enabling us to respond swiftly and effectively to demand volatility. While isolated events occurred toward the end of the month, their impact was limited and geographically concentrated in the Jalisco region, which represents a small portion of our overall operation.” February Cumulative to February 2026 2025 Var vs 2025 2026 2025 Var vs 2025 Passengers (itinerary + charter, thousands) Domestic1,159 1,195 -3.00% 2,458 2,551 -3.60%International584 569 2.70% 1,339 1,304 2.70%Total1,744 1,764 -1.20% 3,797 3,855 -1.50% ASMs (itinerary + charter, millions) Domestic800 830 -3.60% 1,692 1,755 -3.60%International1,795 1,823 -1.60% 3,906 3,971 -1.60%Total2,595 2,653 -2.20% 5,598 5,726 -2.20% RPMs (itinerary + charter, millions) Domestic652 669 -2.60% 1,392 1,448 -3.90%International1,492 1,449 3.00% 3,366 3,255 3.40%Total2,144 2,118 1.20% 4,758 4,703 1.20% Load Factor (itinerary, %)p.p. p.p. Domestic81.50%80.60%0.9 82.30%82.50%-0.2 International83.20%79.50%3.7 86.20%81.90%4.3 Total82.70%79.80%2.8 85.00%82.10%2.9 Figures may not sum to total due to rounding The information included within this report has not been audited and does not provide information on the Company’s future performance. Aeromexico’s future performance depends on many factors and it cannot be inferred that any period’s performance or its year-over-year comparison will be an indicator of similar future performance. Glossary: “RPMs” Revenue Passenger Miles represent one revenue-passenger transported one mile. This includes itinerary and charter flights. The total RPMs equals the number of revenue-passengers transported multiplied by the total distance flown. “ASMs” Available Seat Miles represent the number of available seats multiplied by the distance flown. This metric is an indicator of the airline’s capacity. It equals one seat offered for one mile, whether the seat is used. “Load Factor” equals the number of passengers transported as a percentage of the number of seats offered. It is a measure of the airline’s capacity utilization. This metric considers the total passengers transported and total seats available in itinerary flights only. “Passengers” refers to the total number of passengers transported by the airline. This press release contains certain forward-looking statements that reflect the current views and/or expectations of the Company and its management with respect to its performance, business and future events. We use words such as “believe,” “anticipate,” “plan,” “expect,”, “intend,” “target,” “estimate,” “project,” “predict,” “forecast,” “guideline,” “should” and other similar expressions to identify forward-looking statements, but they are not the only way we identify such statements. Such statements are subject to a number of risks, uncertainties and assumptions. We caution you that a number of important factors could cause actual results to differ materially from the plans, objectives, expectations, estimates and intentions expressed in this release. The Company is under no obligation and expressly disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. About Grupo Aeroméxico Grupo Aeroméxico, S.A.B. de C.V., is a holding company whose subsidiaries are engaged in commercial aviation in Mexico and in the promotion of passenger loyalty programs. Aeroméxico, Mexico’s global airline, operates primarily out of Terminal 2 of the Mexico City International Airport. Its destination network extends across Mexico, the United States, Canada, Central America, South America, Asia, and Europe. Aeroméxico’s current operating fleet includes Boeing 787 and 737 aircraft, as well as Embraer 190. Aeroméxico is a founding member of SkyTeam, an alliance celebrating 25 years and offering connectivity across more than 145 countries through its 18 partner airlines. www.aeromexico.com www.skyteam.com Contact: [email protected]
	2026-03-05 21:06 6d ago	2026-03-05 16:02 6d ago	GDEV announces preliminary, unaudited results for the fourth quarter and twelve months of 2025	stocknewsapi	GDEV
LIMASSOL, Cyprus, March 05, 2026 (GLOBE NEWSWIRE) -- GDEV Inc. (NASDAQ: GDEV), an international gaming and entertainment company (“GDEV” or the “Company”) released its preliminary, unaudited financial and operational results for the fourth quarter and twelve months ended December 31, 2025. Fourth quarter 2025 financial highlights: Revenue of $90 million decreased by 8% year-over-year.Selling and marketing expenses of $35 million decreased by 25% year-over-year.Profit for the period, net of tax, of $14 million in Q4 2025 increased vs. $2 million in Q4 2024.Adjusted EBITDA1 of $15 million in Q4 2025 increased vs. $9 million in Q4 2024. Fourth quarter and twelve months 2025 financial performance in comparison US$ millionQ4 2025Q4 2024Change (%)12M 202512M 2024Change (%)Revenue9098(8%)404421(4%)Platform commissions(18)(21)(13%)(85)(91)(7%)Game operation cost(15)(13)13%(57)(51)12%Selling and marketing expenses(35)(47)(25%)(159)(209)(24%)General and administrative expenses(9)(8)14%(35)(32)10%Profit/loss for the period, net of tax142N/M6926N/MAdjusted EBITDA215966%794287%Cash flows (used in)/generated from operating activities185N/M29293% Fourth quarter 2025 financial performance In the fourth quarter of 2025 our revenue decreased by $8 million (or 8%) year-over-year and amounted to $90 million, reflecting a decline in recognition of revenue from both current-period and prior-period bookings. This was mainly due to declining consumer spending levels in the current and preceding years, which reduced the amount of revenue recognized during the quarter. The decrease is consistent with our strategy to pursue more disciplined marketing spending and focus on attracting higher-quality, better-paying users rather than maximizing short-term volume. Platform commissions decreased by $3 million (or 13%) in the fourth quarter of 2025 to reach $18 million, generally proportionate to the decrease in revenues. Game operation cost increased by $2 million in the fourth quarter of 2025 and amounted to $15 million, mainly driven by an increase in investments in our IT infrastructure. Selling and marketing expenses decreased by $12 million in the fourth quarter of 2025, amounting to $35 million. This decrease was driven by our continued focus on improving the efficiency of user acquisition activities. The decrease reflects a more selective approach to performance marketing, prioritizing channels that attract players with higher long-term value over broadscale campaigns aimed at short-term growth. General and administrative expenses remained relatively stable at $9 million in the fourth quarter of 2025 vs. $8 million in the fourth quarter of 2024. We recorded a profit for the period, net of tax, of $14 million in the fourth quarter of 2025 compared with $2 million in the same period of 2024, driven primarily by the factors above and i.) decrease of net financial expenses in Q4 2025 vs Q4 2024 in the amount of $3 million and ii.) decrease of share of loss of equity accounted associates by $6 million in Q4 2025 as compared with the same period of prior year. Adjusted EBITDA amounted to $15 million in the fourth quarter of 2025, an increase of $6 million compared with the same period in 2024 driven primarily by the same factors as those affecting the profit, except for the decrease of share of loss of equity accounted associates, which does not impact Adjusted EBITDA. Cash flows generated from operating activities were positive $18 million in the fourth quarter of 2025 compared with positive $5 million in the same period in 2024. Twelve months 2025 financial performance In the year ended December 31, 2025, our revenue decreased by $17 million (or 4%) year-over-year and amounted to $404 million, reflecting a decline in recognition of revenue from both current-period and prior-period bookings. This was mainly due to declining consumer spending levels in the current and preceding years, which reduced the amount of revenue recognized during the year. The decrease is consistent with our strategy to pursue more disciplined marketing spending and focus on attracting higher-quality, better-paying users rather than maximizing short-term volume. Platform commissions decreased by $7 million (or 7%) in the year ended December 31, 2025 to reach $85 million, generally proportionate to the decrease in revenues. Game operation cost increased by $6 million in the year ended December 31, 2025 and amounted to $57 million, mainly driven by an increase in investments in our IT infrastructure. Selling and marketing expenses decreased by $50 million in the year ended December 31, 2025, amounting to $159 million. This decrease was driven by our continued focus on improving the efficiency of user acquisition activities. The decrease reflects a more selective approach to performance marketing, prioritizing channels that attract players with higher long-term value over broadscale campaigns aimed at short-term growth. General and administrative expenses increased by $3 million in the year ended December 31, 2025 and amounted to $35 million vs. $32 million in the year ended December 31, 2024. The increase was primarily driven by higher salary and related personnel expenses, reflecting the expansion of development activities and increased scale of operations across our game development studios. We recorded a profit for the period, net of tax, of $69 million in the year ended December 31, 2025 compared with $26 million in the same period of 2024, driven primarily by the factors above and i.) decrease of net financial expenses in the year ended December 31 2025 vs the same period in 2024 in the amount of $7 million, ii.) increase in gain resulted from the change in fair value of share warrant obligation and other financial instruments by $3 million in the year ended December 31 2025 as compared with the same period of prior year and iii.) decrease of share of loss of equity accounted associates by $4 million in the year ended December 31, 2025 as compared with the same period of prior year. Adjusted EBITDA amounted to $79 million in the year ended December 31, 2025, an increase $37 million compared with the same period in 2024 driven primarily by the same factors as those affecting the profit, except for the increase in gain resulted from the change in fair value of share warrant obligation and other financial instruments and the decrease of share of loss of equity accounted associates, which do not impact Adjusted EBITDA. Cash flows generated from operating activities remained the same, at $29 million, in the year ended December 31, 2025 vs. the same period of 2024. The divergence in earnings and cash flow dynamics reflects the significant impact of deferred revenue recognition on current-period income, which did not have a material effect on current-period cash flows. Fourth quarter and twelve months 2025 operational performance comparison Q4 2025Q4 2024Change (%)12M 202512M 2024Change (%)Bookings ($ million)8894(7%)351404(13%)Bookings from in-app purchases8389(6%)331377(12%)Bookings from advertising45(18%)2027(25%)Share of advertising5.1%5.8%(0.7) p.p5.7%6.7%(1.0) p.p.MPU (thousand)262292(10%)281342(18%)ABPPU ($)1061024%98927% Bookings declined in the fourth quarter and twelve months of 2025 to reach $88 million and $351 million, respectively, compared with $94 million and $404 million in the same period in 2024. The decline is primarily due to a decline in monthly paying users by 10% in the fourth quarter of 2025 vs. the same period in 2024 and by 18% in the year ended December 31, 2025 vs. the same period in 2024, which we attribute to the decrease of the user acquisition investments throughout 2024 and 2025, partially offset by an increase in ABPPU. The share of advertisement sales as a percentage of total bookings decreased in the fourth quarter of 2025 to reach 5.1% compared to 5.8% in the same respective period in 2024 and decreased in the year ended December 31, 2025 to reach 5.7% compared to 6.7% in the same period in 2024. This decline was primarily driven by a global trend of declining CPM rates for advertising throughout 2024 and 2025. Split of bookings by platformQ4 2025Q4 202412M 202512M 2024Mobile58%57%60%60%PC42%43%40%40% In the fourth quarter of 2025 we recorded an increase in share of mobile to reach 58% vs. 57% in the same period in 2024 and decrease in share of PC to reach 42% vs. 43% in the same period in 2024. In the year ended December 31, 2025 the share in mobile and PC remained the same compared to same period in 2024. Split of bookings by geographyQ4 2025Q4 202412M 202512M 2024US30%34%33%34%Asia18%21%19%22%Europe34%32%33%30%Other18%13%15%14% Our split of bookings by geography in the fourth quarter and twelve months of 2025 vs. the same respective periods in 2024 saw a decrease in the share of bookings derived from the US and Asia and an increase in bookings derived from Europe and Other. Note: Due to rounding, the numbers presented throughout this release may not precisely add up to the totals. The period-over-period percentage changes are based on the actual numbers and may therefore differ from the percentage changes if those were to be calculated based on the rounded numbers. The figures in this release are preliminary and unaudited. The Company’s 2025 Annual Report on Form 20-F, which will include the Company’s audited financial statements as of for the year ended December 31, 2025, is expected to be published within the prescribed filing period. About GDEV GDEV is a gaming and entertainment holding company, focused on development and growth of its franchise portfolio across various genres and platforms. With a diverse range of subsidiaries including Nexters and Cubic Games, among others, GDEV strives to create games that will inspire and engage millions of players for years to come. Its franchises, such as Hero Wars, Island Hoppers, Pixel Gun 3D and others have accumulated over 550 million installs and more than $2.5 billion of bookings worldwide. For more information, please visit www.gdev.inc. Contacts: Investor Relations Roman Safiyulin \| Chief Corporate Development Officer [email protected] Cautionary statement regarding forward-looking statements Certain statements in this press release may constitute “forward-looking statements” for purposes of the federal securities laws. Such statements are based on current expectations that are subject to risks and uncertainties. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The forward-looking statements contained in this press release are based on the Company’s current expectations and beliefs concerning future developments and their potential effects on the Company. There can be no assurance that future developments affecting the Company will be those that the Company has anticipated. Forward-looking statements involve a number of risks, uncertainties (some of which are beyond the Company’s control) or other assumptions. You should carefully consider the risks and uncertainties described in the “Risk Factors” section of the Company’s 2024 Annual Report on Form 20-F, filed by the Company on March 31, 2025, and other documents filed by the Company from time to time with the Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should any of the Company’s assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Presentation of Non-IFRS Financial Measures In addition to the results provided in accordance with IFRS throughout this press release, the Company has provided the non-IFRS financial measure “Adjusted EBITDA” (the “Non-IFRS Financial Measure”). The Company defines Adjusted EBITDA as the profit/loss for the period, net of tax as presented in the Company's financial statements in accordance with IFRS, adjusted to exclude (i) goodwill and investments in equity-accounted associates' impairment, (ii) loss on disposal of subsidiaries, (iii) income tax expense, (iv) other financial income, finance income and expenses other than foreign exchange gains and losses and bank charges, (v) change in fair value of share warrant obligations and other financial instruments, (vi) share of loss of equity-accounted associates, (vii) depreciation and amortization, (viii) share-based payments expense and (ix) certain non-cash or other special items that we do not consider indicative of our ongoing operating performance. The Company uses this Non-IFRS Financial Measure for business planning purposes and in measuring its performance relative to that of its competitors. The Company believes that this Non-IFRS Financial Measure is a useful financial metric to assess its operating performance from period-to-period by excluding certain items that the Company believes are not representative of its core business. This Non-IFRS Financial Measure is not intended to replace, and should not be considered superior to, the presentation of the Company’s financial results in accordance with IFRS. The use of the Non-IFRS Financial Measure terms may differ from similar measures reported by other companies and may not be comparable to other similarly titled measures. Reconciliation of the profit for the period, net of tax to the Adjusted EBITDA US$ millionQ4 2025Q4 202412M 202512M 2024Profit for the period, net of tax1426926Adjust for: Income tax expense0.9155Adjusted finance income/expenses3(0.2)0.7(3)(2)Share of loss of equity-accounted associates2(1)548Change in fair value of share warrant obligations and other financial instruments(0.2)(0.6)(4)(0.9)Depreciation and amortization2276Share-based payments0.10.20.61Adjusted EBITDA1597942 ______________________________ 1 For more information, see section titled “Presentation of Non-IFRS Financial Measures” on the last two pages of this report, including the reconciliation of the profit for the period, net of tax to the Adjusted EBITDA. 2 The financial information presented for the comparative periods of 2024 may not reconcile exactly with the amounts previously published for those periods. This is due to the reclassification of the Impairment loss on loan receivables from Royal Ark to the Share of loss of equity-accounted associates line. 3 Adjusted finance income/expenses consist of finance income and expenses other than foreign exchange gains and losses and bank charges, net.
	2026-03-05 21:06 6d ago	2026-03-05 16:02 6d ago	Bridger Aerospace Announces Record 2025 Results: Revenue Grows 25%, Adjusted EBITDA up 21% Year-Over-Year and Delivers Positive Net Income	stocknewsapi	BAER
BELGRADE, Mont., March 05, 2026 (GLOBE NEWSWIRE) -- Bridger Aerospace Group Holdings, Inc. (“Bridger”, “the Company” or “Bridger Aerospace”), (NASDAQ: BAER, BAERW), one of the nation’s largest aerial firefighting companies, today reported financial results for the fourth quarter and year ended December 31, 2025, including positive net income for the full year. Highlights: Revenue for 2025 grew 25% to $122.8 million, surpassing the company’s increased guidance rangePositive Net Income for 2025 was $4.1 million, with adjusted EBITDA increasing 21% from 2024 to $45.3 millionCompleted $331.5 million financing package, including debt refinancing and a $100.0 million delayed draw facility, to bolster financial flexibility and fund strategic fleet expansion amid rising demand for aerial firefighting servicesFleet expansion program advanced with the addition of the first two Spanish Scoopers to the operational fleet and four additional air surveillance aircraft added to the balance sheetInitiating 2026 guidance: Revenue expected to be between $135 million and $145 million, representing 14% growth at the midpoint of the range and growth of 29% when excluding non-recurring return to service work on the Spanish Scoopers in 2025Adjusted EBITDA range of $55 million to $60 million representing growth of 27% at the midpoint of the range Summary Financial Results (In thousands) For the three months ended December 31, For the year ended December 31, 2025 2024 2025 2024 Revenues $8,547 $15,585 $122,830 98,613 Net (loss) income (15,149) (12,845) 4,140 (15,567) Adjusted EBITDA (9,543) (2,901) 45,278 37,336 Net cash provided by operating activities 16,732 9,355 Cash and cash equivalents $31,381 $39,336 “Our record financial performance in 2025, during a statistically below-average fire year, underscores the strength of our business model, growing diversification of our revenue stream and the benefits of longer-term contacts for our aircraft,” shared Sam Davis, Bridger’s Chief Executive Officer. “Our customers’ growing emphasis on early detection, combined with our outstanding team, helped drive the increased prepositioning and enhanced utilization of our fleet in 2025. As we complete fleet maintenance to ensure our year-round readiness, we are well positioned for another record year, both operationally and financially. Our new credit facility, including a $100 million Draw Down, further enables us to acquire new aircraft to better fight against the growing threat of wildfire, fulfill customer requests, and advance our mission to protect lives, property, critical infrastructure, and the environment.” Fourth Quarter 2025 Results Revenue for the fourth quarter of 2025 was $8.5 million compared to $15.6 million in the fourth quarter of 2024. Excluding $0.8 million of revenue for return to service work performed on the four Spanish Super Scoopers as part of our partnership agreement with MAB Funding, LLC (“MAB”) in the fourth quarter of 2025, revenue was $7.7 million, compared to $10.5 million in the fourth quarter of 2024 after excluding $5.1 million of revenue for return to service work performed under the MAB agreement. The reduction in revenue year over year was also related to later deployment of Super Scoopers in the fourth quarter of 2024, into November. Cost of revenues was $14.1 million in the fourth quarter of 2025 compared to $15.4 million in the fourth quarter of 2024. Selling, general and administrative expenses (“SG&A”) were $13.4 million in the fourth quarter of 2025 compared to $7.7 million in the fourth quarter of 2024, primarily reflecting an increase in the fair value of our warrants and an increase in earnout consideration compared to the fourth quarter of 2024. Interest expense for the fourth quarter of 2025 was $6.0 million compared to $5.9 million in the fourth quarter of 2024. Other income was $10.0 million in the fourth quarter of 2025 compared to $0.3 million in the fourth quarter of 2024. The increase was primarily attributable to a gain of $16.9 million related to the sale-leaseback transaction partially offset by a loss of $7.8 million on the extinguishment of debt in conjunction with our debt refinancing in the fourth quarter of 2025. Net loss was $15.1 million, or ($0.40) per diluted share, in the fourth quarter of 2025 compared to a net loss of $12.8 million, or (0.36) per diluted share, in the fourth quarter of 2024. Adjusted EBITDA was negative ($9.5) million in the fourth quarter of 2025, compared to negative ($2.9) million in the fourth quarter of 2024. Definitions and reconciliations of net (loss) income to EBITDA and Adjusted EBITDA, are attached as Exhibit A to this release. As of December 31, 2025, cash and cash equivalents were $31.4 million compared to $39.3 million as of December 31, 2024. Full Year Results Revenue was $122.8 million compared to $98.6 million in 2024, representing an increase of 25%. Excluding $14.0 million of revenue for return to service work performed on the four Spanish Super Scoopers as part of our partnership agreement with MAB in 2025, revenue was $108.8 million compared to $88.5 million in 2024 after excluding $10.1 million for return to service work performed under the MAB agreement. The increase in revenue was driven by increased activity for our Super Scoopers and surveillance aircraft in 2025, despite what was generally a below average wildfire year. Cost of revenues was $71.1 million in 2025 compared to $57.5 million in 2024. Cost of revenues for 2025 included an increase of $5.4 million of expenses associated with the return-to-service work for the Spanish Super Scoopers compared to 2024. SG&A expenses were $36.3 million in 2025 compared to $35.8 million for 2024, reflecting an increase in the fair value of our warrants partially offset by a decrease in non-cash stock-based compensation expense. Interest expense for 2025 was $23.3 million compared to $23.7 million in 2024. Other income was $11.8 million in 2025 compared to $2.1 million in 2024. The increase was primarily attributable to a gain of $16.9 million related to the sale-leaseback transaction partially offset by a loss of $7.8 million on the extinguishment of debt in conjunction with our debt refinancing in the fourth quarter of 2025. Net income was $4.1 million in 2025 compared to a net loss of $15.6 million in 2024. Adjusted EBITDA was $45.3 million in 2025, compared to $37.3 million in 2024. Business Outlook With the addition of four Air Surveillance aircraft, including two that were previously leased with two remaining years on contract, and the first two Spanish Scoopers added to our fleet, we anticipate revenue of $135 million to $145 million in 2026, up 29% at the midpoint of the range and excluding revenue associated with return to service work in 2025. This is expected to drive Adjusted EBITDA to $55 million to $60 million, growth of 27% at the midpoint of the range. Definitions and reconciliations of net loss to EBITDA and Adjusted EBITDA, are attached as Exhibit A to this release. Conference Call Bridger Aerospace will hold an investor conference call on Thursday, March 5, 2026, at 5:00 p.m. Eastern Time (3:00 p.m. Mountain Time) to discuss these results and its business outlook. Interested parties can access the conference call by dialing 800-245-3047 or 203-518-9765. The conference call will also be broadcast live on the Investor Relations section of our website at https://ir.bridgeraerospace.com. An audio replay will be available through March 12, 2026, by calling 844-512-2921 or 412-317-6671 and using the passcode 11160880. The replay will also be accessible at https://ir.bridgeraerospace.com. About Bridger Aerospace Based in Belgrade, Montana, Bridger Aerospace Group Holdings, Inc. is one of the nation’s largest aerial firefighting companies. Bridger provides aerial firefighting and wildfire management services to federal and state government agencies, including the United States Forest Service, across the nation, as well as internationally. More information about Bridger Aerospace is available at https://www.bridgeraerospace.com. Investor Contacts Alison Ziegler Darrow Associates 201-220-2678 [email protected] Forward-Looking Statements Certain statements included in this press release that are not historical facts (including any statements concerning plans and objectives of management for future operations of economic performance, or assumptions or forecasts related thereto) are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended and the Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “project,” “forecast,” “predict,” “poised,” “positioned,” “potential,” “seem,” “seek,” “future,” “outlook,” “target,” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include, but are not limited to, 1) the anticipated expansion of Bridger’s operations and increased deployment of Bridger’s aircraft fleet, the anticipated benefits therefrom and the ultimate structure of such acquisitions and/or right to use arrangements; (2) Bridger’s business and growth plans and future financial performance; (3) current and future demand for aerial firefighting services, including the duration or severity of any domestic or international wildfire seasons; (4) the magnitude, timing and benefits from any cost reduction actions; (5) Bridger’s exploration of, need for, or completion of any future financings; (6) Bridger’s potential sources of liquidity and capital resources; and (7) anticipated investments in additional aircraft, capital resources and research and development and the effect of these investments. These statements are based on various assumptions and estimates, whether or not identified in this press release, and on the current expectations of Bridger’s management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by any investor as a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of Bridger. These forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to: the ability of Bridger to successfully implement the benefits from the financing transactions; Bridger’s ability to identify and effectively implement any current or future anticipated cost reductions, including any resulting impacts to Bridger’s business and operations therefrom; the duration or severity of any domestic or international wildfire seasons; changes in domestic and foreign business, market, financial, political and legal conditions; Bridger’s failure to realize the anticipated benefits of any acquisitions; Bridger’s successful integration of any aircraft (including achievement of synergies and cost reductions); Bridger’s ability to successfully and timely develop, sell and expand its services, and otherwise implement its growth strategy; risks relating to Bridger’s operations and business, including information technology and cybersecurity risks, loss of requisite licenses, flight safety risks, loss of key customers and deterioration in relationships between Bridger and its employees; risks related to increased competition; risks relating to potential disruption of current plans, operations and infrastructure of Bridger, including as a result of the consummation of any acquisition; risks that Bridger is unable to secure or protect its intellectual property; risks that Bridger experiences difficulties managing its growth and expanding operations; Bridger's ability to compete with existing or new companies that could cause downward pressure on prices, fewer customer orders, reduced margins, the inability to take advantage of new business opportunities, and the loss of market share; the ability to successfully select, execute or integrate future acquisitions into Bridger's business, which could result in material adverse effects to operations and financial conditions; and those factors discussed in the sections entitled “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” included in Bridger’s Annual Report filed with the U.S. Securities and Exchange Commission (the “SEC”) on March 14, 2025 for the fiscal year ended December 31, 2024 and in subsequent filings made by Bridger with the SEC from time to time. If any of these risks materialize or Bridger management's assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. The risks and uncertainties above are not exhaustive, and there may be additional risks that Bridger presently does not know or that Bridger currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect Bridger’s expectations, plans or forecasts of future events and views as of the date of this press release. Bridger anticipates that subsequent events and developments will cause Bridger’s assessments to change. However, while Bridger may elect to update these forward-looking statements at some point in the future, Bridger specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Bridger’s assessments as of any date subsequent to the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements contained in this press release. BRIDGER AEROSPACE GROUP HOLDINGS, INC.CONSOLIDATED STATEMENTS OF OPERATIONS(In thousands, except per share amounts)(Unaudited) For the three months ended December 31, For the year ended December 31, 2025 2024 2025 2024 Revenues $8,547 $15,585 $122,830 $98,613 Cost of revenues: Flight operations 5,707 5,779 31,933 31,016 Maintenance 8,400 9,622 39,214 26,459 Total cost of revenues 14,107 15,401 71,147 57,475 Gross (loss) income (5,560) 184 51,683 41,138 Selling, general and administrative expense 13,446 7,667 36,283 35,820 Interest expense 5,989 5,948 23,263 23,714 Other income 10,038 294 11,788 2,067 (Loss) income before income taxes (14,957) (13,137) 3,925 (16,329) Income tax (expense) benefit (192) 292 215 762 Net (loss) income $(15,149) $(12,845) $4,140 $(15,567) Series A preferred stock – adjustment to maximum redemptions value (6,942) (6,478) (27,078) (25,339) Loss attributable to Common stockholders - basic and diluted $(22,091) $(19,323) $(22,938) $(40,906) Loss per share - basic $(0.40) $(0.36) $(0.42) $(0.81)Loss per share - diluted $(0.40) $(0.36) $(0.42) $(0.81) Weighted average Common stock outstanding – basic 54,788 53,180 54,283 50,525 Weighted average Common stock outstanding – diluted 54,788 53,180 54,283 50,525 BRIDGER AEROSPACE GROUP HOLDINGS, INC.CONSOLIDATED BALANCE SHEETS(In thousands)(Unaudited) As of December 31, 2025 As of December 31, 2024ASSETS Current assets: Cash and cash equivalents$31,381 $39,336 Restricted cash - 13,747 Accounts and note receivable 3,190 5,945 Aircraft support parts 1,654 857 Prepaid expenses and other current assets 3,994 3,924 Total current assets 40,219 63,809 Property, plant and equipment, net 218,814 183,769 Intangible assets, net 6,023 6,076 Goodwill 20,888 20,749 Other noncurrent assets 44,362 16,406 Total assets$330,306 $290,809 LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS’ DEFICIT Current liabilities: Accounts payable$3,417 $5,330 Accrued expenses and other current liabilities 9,794 14,057 Operating right-of-use current liability 2,384 1,835 Current portion of long-term debt, net of debt issuance costs 926 2,170 Total current liabilities 16,521 23,392 Long-term accrued expenses and other noncurrent liabilities 7,576 5,388 Operating right-of-use noncurrent liability 29,163 6,083 Long-term debt, net of debt issuance costs 212,380 202,469 Total liabilities$265,640 $237,332 COMMITMENTS AND CONTINGENCIES MEZZANINE EQUITY Series A preferred stock 407,257 380,179 STOCKHOLDERS’ DEFICIT Common stock 6 6 Additional paid-in capital 82,315 101,495 Accumulated deficit (425,099) (429,239)Accumulated other comprehensive income 187 1,036 Total stockholders’ deficit (342,591) (326,702)Total liabilities, mezzanine equity, and stockholders’ deficit$330,306 $290,809 BRIDGER AEROSPACE GROUP HOLDINGS, INC.CONSOLIDATED STATEMENTS OF CASH FLOWS(In thousands)(Unaudited) For the year ended December 31, 2025 2024 Cash Flows from Operating Activities: Net income (loss)$4,140 $(15,567)Adjustments to reconcile net income (loss) to net cash provided by operating activities, net of acquisition: Depreciation and amortization 15,471 17,451 Gain on sale-leaseback transaction (16,876) - Loss on debt extinguishment 7,776 - Stock based compensation expense 7,098 16,160 Change in fair value of the Warrants 4,264 (4,530)Amortization of debt issuance costs 1,096 943 Impairment of long-lived assets 178 - Loss on termination of interest rate swap 59 - (Gain) loss on disposal of fixed assets (87) 386 Change in fair value of earnout consideration (2,285) (393)Reclassification of realized gain on derivative instruments from AOCI (698) - Deferred tax benefit (373) (1,142)Realized gain on investments in marketable securities - (16)Change in fair value of embedded derivative - (885)Changes in operating assets and liabilities: Accounts receivable 2,755 (2,133)Aircraft support parts (797) (104)Prepaid expense and other current and noncurrent assets 2,345 2,286 Accounts payable, accrued expenses and other liabilities (7,334) (3,101)Net cash provided by operating activities 16,732 9,355 Cash Flows from Investing Activities: Proceeds from sale-leaseback transaction, net 46,849 - Sale of property, plant and equipment 976 649 Purchases and improvements of property, plant and equipment (80,942) (4,084)Capitalized costs related to in-process research and development (1,326) (1,156)Collection of note receivable - 3,000 Cash acquired through acquisition - 2,592 Proceeds from sales and maturities of marketable securities - 1,055 Net cash (used in) provided by investing activities (34,443) 2,056 Cash Flows from Financing Activities: Proceeds from issuance of term loans 220,251 - Termination of interest rate swap 639 - Repayments on debt (210,942) (2,988)Payment of issuance costs for term loans (13,850) - Cash paid for taxes related to net share settlement of equity awards (391) (644)Payment of finance lease liability (27) (26)Proceeds from issuance of Common Stock in the registered direct offering - 9,169 Proceeds from issuance of Common Stock in the at-the-market offering - 168 Payment of issuance costs for Common Stock in offerings - (1,006)Net cash (used in) provided by financing activities (4,320) 4,673 Effects of exchange rate changes 329 62 Net change in cash, cash equivalents and restricted cash (21,702) 16,146 Cash, cash equivalents and restricted cash – beginning of the period 53,083 36,937 Cash, cash equivalents and restricted cash – end of the period$31,381 $53,083 Less: Restricted cash – end of the period - 13,747 Cash and cash equivalents – end of the period$31,381 $39,336 EXHIBIT A Non-GAAP Results and Reconciliations Although Bridger believes that net income or loss, as determined in accordance with GAAP, is the most appropriate earnings measure, we use EBITDA and Adjusted EBITDA as key profitability measures to assess the performance of our business. Bridger believes these measures help illustrate underlying trends in our business and use the measures to establish budgets and operational goals, and communicate internally and externally, in managing our business and evaluating its performance. Bridger also believes these measures help investors compare our operating performance with its results in prior periods in a way that is consistent with how management evaluates such performance. Each of the profitability measures described below is not recognized under GAAP and does not purport to be an alternative to net income or loss determined in accordance with GAAP as a measure of our performance. Such measures have limitations as analytical tools, and you should not consider any of such measures in isolation or as substitutes for our results as reported under GAAP. EBITDA and Adjusted EBITDA exclude items that can have a significant effect on our profit or loss and should, therefore, be used only in conjunction with our GAAP profit or loss for the period. Bridger’s management compensates for the limitations of using non-GAAP financial measures by using them to supplement GAAP results to provide a more complete understanding of the factors and trends affecting the business than GAAP results alone. Because not all companies use identical calculations, these measures may not be comparable to other similarly titled measures of other companies. Bridger does not provide a reconciliation of forward-looking measures where Bridger believes such a reconciliation would imply a degree of precision and certainty that could be confusing to investors and is unable to reasonably predict certain items contained in the GAAP measures without unreasonable efforts, such as acquisition costs, integration costs and loss on the disposal or obsolescence of aging aircraft. This is due to the inherent difficulty of forecasting the timing or amount of various items that have not yet occurred and are out of Bridger’s control or cannot be reasonably predicted. For the same reasons, Bridger is unable to address the probable significance of the unavailable information. Forward-looking non-GAAP financial measures provided without the most directly comparable GAAP financial measures may vary materially from the corresponding GAAP financial measures. EBITDA and Adjusted EBITDA EBITDA is a non-GAAP profitability measure that represents net income or loss for the period before the impact of the interest expense, income tax expense (benefit) and depreciation and amortization of property, plant and equipment and intangible assets. EBITDA eliminates potential differences in performance caused by variations in capital structures (affecting financing expenses), the cost and age of tangible assets (affecting relative depreciation expense) and the extent to which intangible assets are identifiable (affecting relative amortization expense). Adjusted EBITDA is a non-GAAP profitability measure that represents EBITDA before certain items that are considered to hinder comparison of the performance of our businesses on a period-over-period basis or with other businesses. During the periods presented, we exclude from Adjusted EBITDA offering costs related to financing and other transactions, which include costs that are required to be expensed in accordance with GAAP. In addition, we exclude from Adjusted EBITDA non-cash stock-based compensation, business development and integration expenses, the change in the fair value of earnout consideration, the change in the fair value of warrants, the gain on non-recurring transactions and non-recurring organizational development costs. Our management believes that the inclusion of supplementary adjustments to EBITDA applied in presenting Adjusted EBITDA is appropriate to provide additional information to investors about certain material non-cash items and about unusual items that we do not expect to continue at the same level in the future. The following table reconciles net (loss) income, the most directly comparable GAAP measure, to EBITDA and Adjusted EBITDA for the three months and years ended December 31, 2025, and 2024. (In thousands)For the three months ended December 31, For the year ended December 31, 2025 2024 2025 2024 Net (loss) income$(15,149) $(12,845) $4,140 $(15,567)Income tax expense (benefit) 192 (292) (215) (762)Depreciation and amortization 1,275 2,692 15,471 17,451 Interest expense 5,989 5,948 23,263 23,714 EBITDA (7,693) (4,497) 42,659 24,836 Stock-based compensation(1) 2,891 2,442 7,720 16,160 Business development & integration expenses(2) 730 392 1,648 1,140 Offering costs(3) 3 167 440 123 Change in fair value of earnout consideration(4) 496 (872) (2,285) (393)Change in fair value of Warrants(5) 3,198 (533) 4,264 (4,530)Non-cash impairment charges (6) 178 - 178 - Gain on non-recurring transactions(7) (9,738) - (9,738) - Non-recurring organizational development costs(8) 392 - 392 - Adjusted EBITDA$(9,543) $(2,901) $45,278 $37,336 1Represents non-cash stock-based compensation expense associated with employee and non-employee equity awards.2Represents expenses related to integration costs for completed acquisitions and potential acquisition targets and additional business lines.3Represents one-time costs for professional service fees related to the preparation for potential offerings that have been expensed during the period.4Represents non-cash fair value adjustment for earnout consideration issued in connection with the acquisition of Ignis Technologies, Inc. and Flight Test & Mechanical Solutions, Inc.5Represents the non-cash fair value adjustment for the outstanding warrants.6Represents non-cash impairment charges on aircraft.7Represents the net effect from the October debt refinancing and sale-leaseback transactions completed during the period.8Represents expenses associated with the build-out of the executive leadership team.
	2026-03-05 21:06 6d ago	2026-03-05 16:02 6d ago	Pattern Reports Record Fourth Quarter and Full Year 2025 Financial Results; Announces $100 Million Share Repurchase Program	stocknewsapi	PTRN
LEHI, Utah--(BUSINESS WIRE)--Pattern Group Inc. (NASDAQ: PTRN), a leader in accelerating brands on global ecommerce marketplaces leveraging proprietary technology and AI, today announced financial results for the fourth quarter and full year ended December 31, 2025. “2025 was a defining year for Pattern. We delivered record results, exceeding our prior expectations and demonstrating our ability to scale with discipline,” said Dave Wright, Co-Founder and CEO of Pattern. “Our results were driven.
	2026-03-05 21:06 6d ago	2026-03-05 16:02 6d ago	Anthropic growth set to boost Amazon's AWS revenue acceleration, says Bank of America	stocknewsapi	AMZN
Amazon.com Inc (NASDAQ:AMZN) could see an incremental boost to its cloud computing revenue from the rapid growth of artificial intelligence startup Anthropic, according to analysts at Bank of America. In a note to clients, the analysts reiterated a ‘Buy’ rating on Amazon with a $275 price target, citing the potential for stronger-than-expected performance at Amazon Web Services (AWS) as AI demand accelerates. Shares traded hands at about $219 on Thursday. Bloomberg recently reported that Anthropic’s annualized revenue run rate has surpassed $19 billion, up sharply from $9 billion at the end of 2025. The analysts wrote that the increase reflects strong adoption of the company’s AI models and its developer tool Claude Code, alongside the recent launch of its Opus 4.6 model. “Anthropic's ARR reportedly surpassed $19 billion,” the analysts wrote, adding that recent growth has been driven by expanding use of the company’s AI models and tools. The analysts believe Anthropic’s growth could translate into meaningful revenue contributions for AWS, which hosts some of the company’s computing workloads. They estimate the surge in Anthropic’s revenue run rate, from $9 billion in December to $19 billion in March, suggests a quarterly revenue increase of more than $2.5 billion for the AI firm. “If a significant share of Anthropic's workloads run on AWS… we see an opportunity for up to a $1 billion quarter-over-quarter increase in Q1 AWS revenues related to Anthropic,” the analysts wrote. They noted that this potential increase would exceed their broader estimate of roughly $900 million in quarter-over-quarter growth for AWS during the same period. Anthropic is also expected to significantly increase spending on cloud infrastructure. According to a report cited by the analysts, the company could pay hyperscale cloud providers as much as $6.4 billion in 2026 through revenue-sharing agreements tied to reselling its Claude AI models, up from $1.9 billion in 2025. Beyond the near-term impact, the analysts said strong demand for AI services from companies like Anthropic and OpenAI signals continued growth opportunities for AWS. “We believe the recent acceleration in Anthropic's ARR signals strong (and rapidly growing) enterprise demand for AI services,” Bank of America wrote. They added that Amazon’s plans to expand computing capacity could translate into faster revenue growth. Amazon management has previously indicated it expects to double AWS power capacity by 2027, a move the analysts said could help drive upside to current Wall Street revenue estimates for the cloud business. The surge in AI demand may also help address investor concerns about the scale of capital spending required to build out data center infrastructure. “Anthropic's recent ARR acceleration is a positive proof point for all hyperscalers and could help reduce a recent sector overhang on capex investment uncertainty,” the bank's analysts wrote. They added that they remain confident AWS can generate stronger returns on those investments than current market estimates suggest
	2026-03-05 21:06 6d ago	2026-03-05 16:03 6d ago	Viking Therapeutics to Participate at Upcoming Investor Conferences	stocknewsapi	VKTX
, /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will participate at multiple upcoming investor conferences. Details of the company's participation are as follows: Leerink Partners Global Healthcare Conference 2026 Details: Viking management will participate in a fireside chat and in 1-on-1 meetings Conference Date: March 8-11, 2026 Fireside Chat Timing: 10:40 – 11:10 a.m. Eastern on Tuesday, March 10, 2026 Location: Miami, FL 2026 Jefferies Biotech on the Beach Summit Details: Viking management will participate in 1-on-1 meetings Conference Dates: March 10-11, 2026 Location: Miami, FL A live webcast of the Leerink presentation may be accessed via a link on the Viking Therapeutics website in the Investors & Media section under Webcasts. Additionally, a replay of the webcast will be available on the Viking website following the conference. About Viking Therapeutics, Inc. Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders. Viking's research and development activities leverage its expertise in metabolism to develop innovative therapeutics designed to improve patients' lives. Viking's clinical programs include VK2735, a novel dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors for the potential treatment of various metabolic disorders. The company is evaluating its subcutaneous formulation of VK2735 in a Phase 3 obesity program that includes two Phase 3 clinical trials (VANQUISH-1 and VANQUISH-2). Data from a Phase 1 and a Phase 2 trial evaluating subcutaneous VK2735 demonstrated an encouraging safety and tolerability profile as well as positive signs of clinical benefit. Concurrently, the company is evaluating an oral formulation of VK2735 in obesity. Viking is also developing VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders. The compound successfully achieved both the primary and secondary endpoints in a Phase 2b study for the treatment of biopsy-confirmed non-alcoholic steatohepatitis (NASH) and fibrosis. In a Phase 2a trial for the treatment of non-alcoholic fatty liver disease (NAFLD) and elevated LDL-C, patients who received VK2809 demonstrated statistically significant reductions in LDL-C and liver fat content compared with patients who received placebo. The company's newest program is evaluating a series of internally developed dual amylin and calcitonin receptor agonists (or DACRAs) for the treatment of obesity and other metabolic disorders. In the rare disease space, Viking is developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy (X-ALD). In a Phase 1b clinical trial in patients with the adrenomyeloneuropathy (AMN) form of X-ALD, VK0214 was shown to be safe and well-tolerated, while driving significant reductions in plasma levels of very long-chain fatty acids (VLCFAs) and other lipids, as compared to placebo. For more information about Viking Therapeutics, please visit www.vikingtherapeutics.com. SOURCE Viking Therapeutics, Inc.
	2026-03-05 21:06 6d ago	2026-03-05 16:03 6d ago	Viewbix Completes Strategic Acquisition of Quantum X Labs – Securing Advanced Quantum Portfolio	stocknewsapi	VBIX
Tel Aviv, Israel, March 05, 2026 (GLOBE NEWSWIRE) -- The acquisition encompasses Quantum’s proprietary intellectual property portfolio, including an innovative patent for AI-Quantum Error Correction Tel Aviv, Israel, March 5, 2026, (GLOBE NEWSWIRE) -- Viewbix Inc. (Nasdaq: VBIX) (“Viewbix” or the “Company”), an advanced technologies company, recently announced that it has completed the acquisition of 100% of Quantum X Labs Ltd. (“Quantum”), a multi-disciplinary quantum technology hub focused on quantum algorithms, navigation, and atomic clocks, pursuant to the definitive share purchase agreement dated December 15, 2025 (the “Agreement Date”). The acquisition encompasses Quantum’s proprietary intellectual property portfolio, including an innovative patent for AI-Quantum Error Correction. Quantum operates portfolio companies developing innovative solutions in quantum-based navigation (including GPS alternatives), next-generation atomic clocks for precision timing, quantum algorithms for sectors such as transportation, drug discovery, biomedicine, and security, as well as advanced quantum error correction technologies. In connection with the closing, Viewbix issued common stock and pre-funded warrants representing approximately 40% of its capital stock as of the Agreement Date (inclusive of 800,000 shares of common stock issued in a related private placement), with potential additional consideration of up to 12,702,847 shares of the Company’s common stock or pre-funded warrants upon achievement of specified post-closing milestones. In addition to the closing of the Quantum acquisition, Viewbix also closed a private placement of approximately $1.4 million shares of the Company’s common stock and warrants to purchase common stock. In connection with the private placement, the Company issued an aggregate of 800,000 shares of common stock at a price of $1.75 per share. In addition, the Company issued an aggregate of 640,000 common warrants, each exercisable for one share of common stock, at an exercise price of $2.625 per share to the investors in the private placement for no additional consideration. The common warrants are exercisable upon issuance and have a term of 5 years from the issuance date. Aggregate gross proceeds to the Company were approximately $1.4 million, before deducting offering expenses payable by the Company. The Company expects to use the net proceeds from the offering, together with its existing cash, for general corporate purposes and working capital. The closing of the Quantum acquisition and private placement occurred on March 4, 2026. The securities described above were issued and/or sold in private placement transactions not involving a public offering and exempt from the registration requirements of the Securities Act of 1933, as amended (the "Act"), and have not been registered under the Act, or applicable state securities laws. Accordingly, the securities may not be reoffered or resold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Act and such applicable state securities laws. The securities were offered only to accredited investors. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About Viewbix Inc. Viewbix, through certain of its subsidiaries Gix Media Ltd. and Metagramm Software Ltd., operates in the field of digital advertising. Gix Media develops a variety of technological software solutions, which perform automation, optimization and monetization of internet campaigns, for the purposes of acquiring and routing internet user traffic to its customers. Metagramm is a developer of grammatical error correction software. The company offers tools for writing and reviewing, grammar, spelling, punctuation and style features, as well as translation and multilingual dictionaries, using artificial intelligence and machine learning technology. For more information about Viewbix, visit https://view-bix.com/ Forward-Looking Statements This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses the achievement of specified post-closing milestones and the intended use of proceeds from the private placement. Because such statements deal with future events and are based on Viewbix’s current expectations, they are subject to various risks and uncertainties, and actual results, performance or achievements could differ materially from those described in or implied by the statements in this press release. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed in any filings with the SEC. Except as otherwise required by law, Viewbix undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Viewbix is not responsible for the contents of third-party websites. Investor Relations Contacts: Michal Efraty Investor Relations [email protected]
	2026-03-05 21:06 6d ago	2026-03-05 16:03 6d ago	Omada Health Reports Fourth Quarter and Full-Year 2025 Results	stocknewsapi	OMDA
Revenue up 58% in Fourth Quarter, 53% for Year; Member Growth of 55% for Year Achieves Positive Net Income in Fourth Quarter; Significantly Narrows Net Loss for Full Year Delivers Positive Adjusted EBITDA for Full Year SAN FRANCISCO, March 05, 2026 (GLOBE NEWSWIRE) -- Omada Health, Inc. (Nasdaq: OMDA), the virtual between-visit healthcare provider, today reported financial results for the fourth quarter and full year ended December 31, 2025. 2025 Fourth Quarter and Full-Year Highlights Highlights are for the fourth quarter and full year 2025, except where otherwise noted. Total members 886,000 at year end, up 55% year over year Revenue $76 million in the fourth quarter, up 58% year over year$260 million for the full year, up 53% compared with 2024 GLP-1 Leadership Omada has now supported more than 150,000 members on GLP-1s, compared with more than 50,000 at the end of 2024Published research demonstrating the effectiveness of Omada’s programs, including data showing members in our GLP-1 Care Track, compared with published real-world evidence, achieved greater average weight loss and largely maintained weight, on average, one year after discontinuing GLP-1 therapyAnnounced plans in November to launch a new prescribing offering that will combine Omada’s evidence-based behavior change program with medication management for anti-obesity medications, including GLP-1sToday, announced GLP-1 Flex Care, a new option that gives employers a structured way to connect eligible employees with clinical evaluation, prescribing, and ongoing medical oversight for GLP‑1s—alongside Omada’s lifestyle and behavioral support—without taking on employer financial coverage for GLP-1s, providing another flexible pathway to balance access, affordability, and durable outcomes across diverse GLP‑1 coverage strategies Program Innovation During 2025, launched OmadaSpark and Meal Map, AI-powered tools that support members with wellness education alongside our human coachesIn February of 2026, announced Omada for Cholesterol to address a highly prevalent, often under‑treated condition that frequently co‑exists with diabetes, hypertension, and obesity, further strengthening its multi‑condition platform capabilities and expanding the scope of Omada’s cardiometabolic care “Our 2025 performance reflects a pivotal year for Omada, marked by strong growth, important profitability milestones, and continued momentum across our business,” said Sean Duffy, co‑founder and CEO of Omada Health. “We demonstrated GLP‑1 companion support innovation, advanced our member‑facing AI capabilities, and introduced meaningful program expansions—all designed to support our members in achieving durable health improvements and serving as a foundation for progress toward our long‑term mission to bend the curve of chronic disease.” Other Fourth Quarter and Full Year 2025 Financial Highlights Gross margin of 71% in the fourth quarter, up from 67% in Q4 2024, and gross margin of 66% for the year compared with 61% in 2024Non-GAAP gross margin of 73% in the fourth quarter, up from 69% in Q4 2024, and non-GAAP gross margin of 68% for the year compared with 63% in 2024Net income of $5 million in the fourth quarter, compared with a net loss of $8 million in Q4 2024, and a net loss of $13 million for the year compared with a net loss of $47 million in 2024Adjusted EBITDA of $8 million in the fourth quarter, compared with an adjusted EBITDA loss of $4 million in Q4 2024, and adjusted EBITDA of $6 million for the year compared with an adjusted EBITDA loss of $29 million in 2024Cash and cash equivalents of $222 million Please see the Non-GAAP Financial Measures section below and reconciliations of GAAP to non-GAAP measures at the end of this press release. Financial Outlook For the year ending December 31, 2026, Omada expects: Revenue in the range of $312 million to $322 million, with the midpoint representing 22% growth compared with 2025Adjusted EBITDA in the range of $7 million to $15 million We have not provided an outlook for net loss (GAAP) or a reconciliation of expected adjusted EBITDA to net loss (GAAP) because net loss (GAAP) on a forward-looking basis is not available without unreasonable effort due to the potential variability and complexity of the items that are excluded from adjusted EBITDA, such as loss on debt extinguishment; provision for income taxes; depreciation and amortization; share-based compensation; change in fair value of warrant liabilities; amortization of intangible assets; and loss on disposal of property and equipment. Conference Call Omada Health will host a conference call at 1:30 p.m. PT/4:30 p.m. ET today, March 5, 2026, during which management will discuss fourth quarter and full-year 2025 results. A live audio webcast of the call will be available online at https://investors.omadahealth.com. A replay will be available shortly after the conclusion of the call at the same link and will remain accessible for approximately 12 months. Those participating via conference call can pre-register using the following link: https://register-conf.media-server.com/register/BI58c6d7a71730445093f7ea7c02d33e97 About Omada Health Omada Health (Nasdaq: OMDA) is reverse engineering the way healthcare is delivered in America, putting the space between doctor visits–where health is won or lost–at the center of care. Today's healthcare system poorly serves chronic conditions that require ongoing support outside of the exam room, like obesity, diabetes, hypertension, cholesterol, and musculoskeletal conditions. Omada’s virtual-first model combines human-led care teams, connected devices, and AI-enabled technology to deliver personalized care at scale, including support for GLP-1 therapy. Omada has served more than two million members since launch across 2,000+ employers, health plans, pharmacy benefit managers, and health systems. Learn more at omadahealth.com. Cautionary Note Regarding Forward-Looking Statements This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. In some cases, forward-looking statements can be identified by words such as: “anticipate,” “intend,” “plan,” “believe,” “project,” “estimate,” “expect,” “may,” “should,” “will” and similar references to future periods. Examples of forward-looking statements contained in this press release include, but are not limited to, statements we make regarding our GLP-1 leadership, plans to launch a new prescribing offering and the benefits of the offering, program innovation and related capabilities, ability to deliver measurable results, business trends, growth prospects and future financial and operating results, and our financial outlook. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, macroeconomic and industry conditions and other factors. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, but are not limited to, the following: our limited operating history and ability to manage our growth effectively; our history of net losses and ability to maintain profitability; the ability of our programs to achieve and maintain market acceptance; changes in the healthcare industry and competition; the growth and success of our customers and channel partners; the number of individuals covered by our programs and the number of our programs covered by our customers; the level of member engagement in our programs; our ability to maintain and grow customer and channel partner relationships; concentration of a substantial portion of our sales among a limited number of customers and channel partners; our ability to attract new customers and channel partners and increase member enrollment from existing and new customers and channel partners; our ability to increase the size of our organization; our dependence on a limited number of third-party suppliers; the impact of seasonality on our financial results; our ability to achieve widespread brand awareness and the impact of any negative media coverage; our ability to develop and release new programs and services; cybersecurity threats; our dependence on the interoperability of our programs and connected devices with third-party devices, operating systems and applications; changes in laws or regulations or the implementation of existing laws and regulations; compliance with privacy and security laws and regulations; our and our affiliated professional entities’ compliance with healthcare regulatory laws; any modification in U.S. Food and Drug Administration enforcement policies; our dependence on our relationships with affiliated professional entities; and other risk factors identified in our filings with the Securities and Exchange Commission (the “SEC”), including our Annual Report on Form 10-K for the year ended December 31, 2025, which is being filed at or around the date hereof. All forward-looking statements in this press release are based only on information currently available to us and speak only as of the date on which they are made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise, except as required under applicable law. Investor Relations Contact: Allan Kells [email protected] Media Contact: Rose Ramseth [email protected] Omada Health, Inc.Consolidated Balance Sheets (in thousands, except share and per-share amounts)(unaudited) As of December 31, 2025 2024 Assets Current assets Cash and cash equivalents$222,036 $76,392 Accounts receivable, net(1) 34,585 23,417 Inventory 4,486 3,296 Deferred commissions, current 3,539 3,017 Prepaid expenses and other current assets(2) 8,288 6,937 Total current assets 272,934 113,059 Property and equipment, net 7,942 5,625 Operating lease right-of-use asset - 447 Deferred commissions, non-current 8,711 9,214 Intangible assets, net 2,414 4,263 Goodwill 13,240 13,240 Other assets 165 5,044 Total assets$305,406 $150,892 Liabilities, redeemable convertible preferred stock and stockholders’ equity (deficit) Current liabilities Accounts payable(3)$10,276 $4,168 Accrued expenses and other current liabilities(4) 40,392 29,840 Operating lease liability, current - 415 Deferred revenue(5) 25,058 19,530 Total current liabilities 75,726 53,953 Long term debt - 29,771 Warrant liabilities, non-current - 2,252 Other liabilities, non-current - 285 Total liabilities 75,726 86,261 Commitments and contingencies Redeemable convertible preferred stock, $0.001 par value per share; no shares and 120,689 shares authorized as of December 31, 2025 and December 31, 2024, respectively; no shares and 118,219 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively; aggregate liquidation preference of $0 and $455,588 as of December 31, 2025 and December 31, 2024, net of issuance costs - 449,034 Stockholders’ equity (deficit) Common stock, $0.001 par value per share; 750,000 and 181,500 shares authorized as of December 31, 2025 and December 31, 2024, respectively; 58,429 and 8,157 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively 58 8 Additional paid-in capital 686,366 59,555 Accumulated deficit (456,744) (443,966)Total stockholders’ equity (deficit) 229,680 (384,403)Total liabilities, redeemable convertible preferred stock and stockholders’ equity (deficit)$305,406 $150,892 (1) Includes amounts from a related party of $22.8 million and $13.2 million as of December 31, 2025 and December 31, 2024, respectively. (2) Includes amounts from a related party of $0.3 million and $0.1 million as of December 31, 2025 and December 31, 2024, respectively. (3) Includes amounts from a related party of $1.0 million and $0 as of December 31, 2025 and December 31, 2024, respectively. (4) Includes amounts from a related party of $4.9 million and $2.2 million as of December 31, 2025 and December 31, 2024, respectively. (5) Includes amounts from a related party of $18.8 million and $13.2 million as of December 31, 2025 and December 31, 2024, respectively. Omada Health, Inc.Consolidated Statements of Operations and Comprehensive Loss (in thousands, except per-share data)(unaudited) Three Months Ended December 31, Year Ended December 31, 2025 2024 2025 2024 Revenue Services(1)$71,651 $45,438 $241,043 $157,789 Hardware(2) 4,195 2,540 19,167 12,011 Total revenue 75,846 47,978 260,210 169,800 Cost of revenue Services(3) 13,768 10,834 51,839 42,520 Hardware 8,416 5,011 37,432 24,403 Total cost of revenue 22,184 15,845 89,271 66,923 Gross profit 53,662 32,133 170,939 102,877 Operating expenses Research and development(4) 11,552 9,190 40,683 35,923 Sales and marketing(5) 24,613 18,089 90,044 68,053 General and administrative(6) 14,216 11,954 52,184 42,555 Total operating expenses 50,381 39,233 182,911 146,531 Operating income (loss) 3,281 (7,100) (11,972) (43,654)Other income (expense), net Interest expense (13) (1,097) (2,534) (4,506)Interest income 1,891 174 5,305 805 Loss on debt extinguishment - - (2,109) - Change in fair value of warrant liabilities - (227) (1,468) 218 Total other expense, net 1,878 (1,150) (806) (3,483)Income (loss) before provision for income taxes 5,159 (8,250) (12,778) (47,137)Provision for income taxes - - - - Net income (loss) and comprehensive income (loss)$5,159 $(8,250) $(12,778) $(47,137) Net income (loss) per share Basic$0.09 $(1.04) $(0.35) $(6.11)Diluted$0.08 $(1.04) $(0.35) $(6.11) Weighted-average shares outstanding Basic 58,056 7,951 36,639 7,721 Diluted 63,930 7,951 36,639 7,721 (1) Includes amounts from a related party of $49.5 million and $25.9 million for the three months ended December 31, 2025 and 2024, respectively and $157.7 million and $88.0 million for the year ended December 31, 2025 and 2024, respectively. (2) Includes amounts from a related party of $3.1 million and $1.8 million for the three months ended December 31, 2025 and 2024, respectively and $12.1 million and $6.5 million for the year ended December 31, 2025 and 2024, respectively. (3) Includes amounts from a related party of $1.2 million and $0.9 million for the three months ended December 31, 2025 and 2024, respectively and $5.0 million and $3.4 million for the year ended December 31, 2025 and 2024, respectively. (4) Includes amounts from a related party of $0.6 million and $0.4 million for the three months ended December 31, 2025 and 2024, respectively and $2.2 million and $1.7 million for the year ended December 31, 2025 and 2024, respectively. (5) Includes amounts from a related party of $6.8 million and $4.2 million for the three months ended December 31, 2025 and 2024, respectively and $26.1 million and $15.2 million for the year ended December 31, 2025 and 2024, respectively. (6) Includes amounts from a related party of $0.4 million and $0.3 million for the three months ended December 31, 2025 and 2024, respectively and $1.5 million and $1.1 million for the year ended December 31, 2025 and 2024, respectively. Omada Health, Inc.Share-based Compensation Summary (in thousands)(unaudited) Three Months Ended December 31, Year Ended December 31, 2025 2024 2025 2024 Services cost of revenue$65 $57 $169 $219Research and development 594 458 2,228 1,713Sales and marketing 1,255 621 3,918 2,602General and administrative 1,831 1,176 6,640 4,886Total share-based compensation expense$3,745 $2,312 $12,955 $9,420 Omada Health, Inc.Consolidated Statements of Cash Flows (in thousands)(unaudited) Three Months Ended December 31, Year Ended December 31, 2025 2024 2025 2024 Operating activities Net income (loss)$5,159 $(8,250) $(12,778) $(47,137)Adjustments to reconcile net loss to net cash provided by (used in) operating activities Depreciation and amortization 1,447 1,278 5,491 4,803 Share-based compensation 3,745 2,312 12,955 9,420 Loss on debt extinguishment - - 2,109 - Loss on disposal of property and equipment 6 - 8 2 Amortization of debt issuance costs - 98 285 389 Non-cash operating lease expense - 187 447 728 Change in fair value of warrants - 227 1,468 (218)Provision for credit losses(1) (296) 1,009 1,189 1,760 Amortization of deferred commissions 872 742 3,339 2,643 Changes in operating assets and liabilities Accounts receivable(2) 7,157 871 (12,357) (8,805)Inventory (1,338) (1,527) (1,190) 318 Prepaid expenses and other current assets(3) 161 (1,197) (1,409) (1,853)Deferred commissions (1,191) (1,550) (3,510) (6,422)Other non-current assets 70 78 251 409 Accounts payable(4) 4,916 (1,089) 6,289 399 Operating lease liabilities - (202) (415) (783)Accrued expenses and other current liabilities(5) 2,770 3,661 10,552 5,343 Deferred revenue(6) (2,099) (3,180) 5,528 4,645 Other non-current liabilities - 45 - 180 Net cash provided by (used in) operating activities 21,379 (6,487) 18,252 (34,179) Investing activities Purchases of property and equipment (199) (184) (1,322) (596)Capitalized internal-use software costs (1,147) (785) (4,510) (3,267)Net cash used in investing activities (1,346) (969) (5,832) (3,863) Financing activities Proceeds from exercise of stock options 3,375 1,284 9,368 3,329 Payment of deferred offering costs 1 (1,171) (4,283) (4,538)Repayment of Midcap term facility principal - - (30,963) - Payment of debt extinguishment costs - - (1,430) - Proceeds from initial public offering, net of underwriting discounts and commissions - - 160,532 - Net cash provided by (used in) financing activities 3,376 113 133,224 (1,209) Net increase (decrease) in cash and cash equivalents 23,409 (7,343) 145,644 (39,251)Cash and cash equivalents at beginning of period 198,627 83,735 76,392 115,643 Cash and cash equivalents at end of period$222,036 $76,392 $222,036 $76,392 (1) Includes changes in related party balances of $0.5 million and $0.2 million for the three months and year ended December 31, 2025 and 2024, respectively. (2) Includes changes in related party balances of $9.1 million and $5.3 million for the three months and year ended December 31, 2025 and 2024, respectively. (3) Includes changes in related party balances of $0.2 million and $0.1 million for the three months and year ended December 31, 2025 and 2024, respectively. (4) Includes changes in related party balances of $1.0 million and $0 million for the three months and year ended December 31, 2025 and 2024, respectively. (5) Includes changes in related party balances of $2.7 million and $0.7 million for the three months and year ended December 31, 2025 and 2024, respectively. (6) Includes changes in related party balances of $5.7 million and $3.9 million for the three months and year ended December 31, 2025 and 2024, respectively. Non-GAAP Financial Measures We use certain financial measures not calculated in accordance with accounting principles generally accepted in the United States (“GAAP”) to supplement the financial information in our consolidated financial statements, which are presented in accordance with GAAP. These non-GAAP financial measures include non-GAAP gross profit, non-GAAP gross margin, non-GAAP research and development expense, non-GAAP sales and marketing expense, non-GAAP general and administrative expense, non-GAAP operating expenses, non-GAAP operating expenses (as a % of revenue), adjusted EBITDA, adjusted EBITDA margin, and free cash flow. We define non-GAAP gross profit and non-GAAP gross margin as gross profit and gross margin, excluding share-based compensation expense, amortization of intangible assets, and depreciation and amortization. We define non-GAAP general and administrative expenses as total general and administrative expenses reported on our consolidated statements of operations, excluding share-based compensation expense, amortization of intangible assets, depreciation and amortization, and loss on disposal of property and equipment. We define non-GAAP research and development expenses as total research and development expenses reported on our consolidated statements of operations, excluding share-based compensation expense, amortization of intangible assets, depreciation and amortization, and loss on disposal of property and equipment. We define non-GAAP sales and marketing expenses as total sales and marketing expenses reported on our consolidated statements of operations, excluding share-based compensation expense, amortization of intangible assets, depreciation and amortization, and loss on disposal of property and equipment. We define non-GAAP operating expenses as total operating expenses reported on our consolidated statements of operations, excluding share-based compensation expense, amortization of intangible assets, depreciation and amortization, and loss on disposal of property and equipment. We define non-GAAP operating expenses margin as non-GAAP operating expenses divided by GAAP total revenue reported on our consolidated statements of operations. We define adjusted EBITDA as net loss and comprehensive loss reported on our consolidated statements of operations, excluding the impact of interest expense, interest income, change in fair value of warrant liabilities, loss on debt extinguishment, provision for income taxes, share-based compensation expense, amortization of intangible assets, depreciation and amortization, and loss on disposal of property and equipment. Free cash flow is net cash used in operating activities less purchases of property and equipment and capitalized internal-use software costs. We believe these non-GAAP financial measures, when taken collectively with GAAP financial information, are useful to investors and others because they allow for additional information with respect to financial measures used by management in its financial and operational decision-making. However, there are a number of limitations related to the use of non-GAAP financial measures. Our presentation of non-GAAP financial measures may not be comparable to similar measures used by other companies. We encourage investors to carefully consider our results under GAAP, as well as our supplemental non-GAAP information and the reconciliation between these presentations, to more fully understand our business. Please see the tables included at the end of this release for the reconciliation of GAAP to non-GAAP results. Key Metric Total Members: A member is a person who is enrolled in one of our virtual care programs and that generated a billing event in the preceding 12 months. We believe growth in the number of members is a key indicator of the performance of our business for both investors and management as we monitor the performance of our business, as members primarily drive services revenue. The number of members depends, in part, on our ability to successfully market our services to new customers and channel partners, our ability to sell additional programs to existing customers and channel partners, and our ability to promote awareness of our programs among covered individuals and to encourage their enrollment. Reconciliation of GAAP to Non-GAAP Financial Measures The following tables reconcile to the specific items excluded from GAAP metrics in the calculation of non-GAAP metrics for the periods shown below: Omada Health, Inc.Reconciliation of GAAP to Non-GAAP Financial Measures - Adjusted EBITDA (in thousands)(unaudited) Three Months Ended December 31, Year Ended December 31, 2025 2024 2025 2024 (in thousands, except percentages)GAAP net income (loss) and comprehensive income (loss)$5,159 $(8,250) $(12,778) $(47,137)Add: Interest expense 13 1,097 2,534 4,506 Interest income (1,891) (174) (5,305) (805)Change in fair value of warrant liabilities — 227 1,468 (218)Loss on debt extinguishment — — 2,109 — Provision for income taxes — — — — Share-based compensation expense 3,745 2,312 12,955 9,420 Amortization of intangible assets 440 501 1,851 2,007 Depreciation and amortization(1) 1,007 777 3,640 2,796 Loss on disposal of property and equipment 5 — 8 2 Adjusted EBITDA$8,478 $(3,510) $6,482 $(29,429)GAAP net income (loss) and comprehensive income (loss) margin (as a percentage of revenue) 6.8% (17.2)% (4.9)% (27.8)%Adjusted EBITDA margin (as a percentage of revenue) 11.2% (7.3)% 2.5% (17.3)% (1) Depreciation and amortization includes depreciation of property and equipment and amortization of capitalized internal-use software costs Omada Health, Inc.Reconciliation of GAAP to Non-GAAP Financial Measures (in thousands)(unaudited) Three Months Ended December 31, Year Ended December 31, 2025 2024 2025 2024 (in thousands, except percentages)GAAP gross profit$53,662 $32,133 $170,939 $102,877 Add: Share-based compensation expense 65 57 169 219 Amortization of intangible assets 440 438 1,755 1,755 Depreciation and amortization(1) 927 683 3,294 2,406 Non-GAAP gross profit 55,094 33,311 176,157 107,257 GAAP gross margin (as a percentage of revenue) 70.8% 67.0% 65.7% 60.6%Non-GAAP gross margin (as a percentage of revenue) 72.6% 69.4% 67.7% 63.2% (1) Depreciation and amortization includes depreciation of property and equipment and amortization of capitalized internal-use software costs GAAP Research and development expense$11,552 $9,190 $40,683 $35,923 Less: Share-based compensation expense 594 458 2,228 1,713 Depreciation and amortization(1) 27 19 88 83 Non-GAAP research and development expense$10,931 $8,713 $38,367 $34,127 Non-GAAP research and development expense (as a % of revenue) 14% 18% 15% 20% GAAP Sales and marketing expense$24,613 $18,089 $90,044 $68,053 Less: Share-based compensation expense 1,255 621 3,918 2,602 Amortization of intangible assets — 63 94 252 Depreciation and amortization(1) 34 28 121 118 Non-GAAP sales and marketing expense$23,324 $17,377 $85,911 $65,081 Non-GAAP sales and marketing expense (as a % of revenue) 31% 36% 33% 38% GAAP General and administrative expense$14,216 $11,954 $52,184 $42,555 Less: Share-based compensation expense 1,831 1,176 6,640 4,886 Depreciation and amortization(1) 19 47 138 189 Loss on disposal of property and equipment 5 — 8 2 Non-GAAP general and administrative expense$12,361 $10,731 $45,398 $37,478 Non-GAAP general and administrative expense (as a % of revenue) 16% 22% 17% 22% GAAP operating expense$50,381 $39,233 $182,911 $146,531 Less: Share-based compensation expense 3,680 2,255 12,786 9,201 Amortization of intangible assets — 63 94 252 Depreciation and amortization(1) 80 94 347 390 Loss on disposal of property and equipment 5 — 8 2 Non-GAAP operating expense$46,616 $36,821 $169,676 $136,686 GAAP operating expense (as a % of revenue) 66.4% 81.8% 70.3% 86.3%Non-GAAP operating expense (as a % of revenue) 61.5% 76.7% 65.2% 80.5% (1) Depreciation and amortization includes depreciation of property and equipment and amortization of capitalized internal-use software costs Omada Health, Inc. Reconciliation of GAAP Net Cash Provided by Operating Activities to Free Cash Flow (in thousands) (unaudited) Three Months Ended December 31, Year Ended December 31, 2025 2024 2025 2024 Net cash provided by (used in) operating activities$21,379 $(6,487) $18,252 $(34,179)Purchases of property and equipment (199) (184) (1,322) (596)Capitalized internal-use software development costs (1,147) (785) (4,510) (3,267)Free Cash Flow$20,033 $(7,456) $12,420 $(38,042)Other cash flow components: Net cash used in investing activities$(1,346) $(969) $(5,832) $(3,863)Net cash provided by (used in) financing activities$3,376 $113 $133,224 $(1,209)
	2026-03-05 21:06 6d ago	2026-03-05 16:04 6d ago	BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting	stocknewsapi	BCTX
March 05, 2026 16:04 ET \| Source: BriaCell Therapeutics Corp. PHILADELPHIA and VANCOUVER, British Columbia, March 05, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX:BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce the results of its annual general and special meeting of shareholders of the Company (the “Shareholders”) for the year ended July 31, 2025 held on March 5, 2026 (the “Meeting”). A total of 48.31% of the Company’s issued and outstanding common shares (the “Common Shares”) were voted at the Meeting. At the Meeting, the Shareholders overwhelmingly voted in favour of all proposed resolutions, consisting of the re-appointment of MNP LLP as auditors of the Company for the ensuing year and authorizing the directors to fix their remuneration, and the election of each of Dr. William V. Williams, Mr. Jamieson Bondarenko, Dr. Jane A. Gross, Dr. Rebecca Taub, Mr. Vaughn C. Embro-Pantalony, and Mr. Martin E. Schmieg as directors of the Company. Detailed results of the votes in connection with the election of the directors are set out below: Director % of Votes For % of Votes WithheldDr. William V. Williams 97.38% 2.62%Mr. Jamieson Bondarenko 97.92% 2.08%Dr. Jane A. Gross 97.36% 2.64%Dr. Rebecca Taub 97.39% 2.61%Mr. Vaughn C. Embro-Pantalony 97.91% 2.09%Mr. Martin E. Schmieg 97.73% 2.27% The formal report on voting results with respect to all matters voted upon during the Meeting will be filed on the Company’s SEDAR+ profile at www.sedarplus.ca. About BriaCell Therapeutics Corp. BriaCell is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. More information is available at https://briacell.com/. Safe Harbor This press release contains “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on BriaCell’s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully under the heading “Risk Factors” in the Company’s most recent Annual Report on Form 10-K, and under “Risks and Uncertainties” in the Company’s other filings with the Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission, all of which are available under the Company’s profiles on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov. Forward-looking statements contained in this announcement are made as of this date, and BriaCell Therapeutics Corp. undertakes no duty to update such information except as required under applicable law. Neither the Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release. Contact Information Company Contact: William V. Williams, MD President & CEO 1-888-485-6340 [email protected] Investor Relations Contact: [email protected]
	2026-03-05 21:06 6d ago	2026-03-05 16:05 6d ago	CAMP4 Reports Full Year 2025 Financial Results and Corporate Highlights	stocknewsapi	CAMP
March 05, 2026 16:05 ET \| Source: CAMP4 Therapeutics GLP toxicology studies ongoing for CMP-002, with initiation of global Phase 1/2 clinical trial in SYNGAP1 patients expected as early as 2H 2026 Entered strategic collaboration with GSK to advance RNA-based therapeutic discoveries, received $17.5 million upfront and eligible for milestone-based payments in addition to tiered royalties Completed private placement with upfront gross proceeds of $50 million, with potential for up to an additional $50 million of gross proceeds, as well as underwritten offering of common stock of $30 million in gross proceeds, extending cash runway into 2028 CAMBRIDGE, Mass., March 05, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced financial results for the full year ended December 31, 2025, and provided recent corporate highlights. "In 2025, we brought our SYNGAP1 program to the forefront of our pipeline and made significant progress against our goal of bringing a potential first-in-class treatment for SYNGAP1-related disorder into the clinic,” said Josh Mandel-Brehm, President and Chief Executive Officer of CAMP4. “Our GLP toxicology studies for CMP-002 are ongoing, and we continue to expect to initiate a global first-in-human Phase 1/2 clinical trial as early as the second half of 2026. We also made progress in our mission of developing potentially disease modifying medicines for patients with disorders marked by suboptimal gene expression by exploring new candidates for both in-house development and potential partnerships and signed a collaboration agreement with GSK to identify and develop ASO drug candidates for multiple gene targets relevant to neurodegenerative and kidney disease indications. Finally, we strengthened our balance sheet through a combination of equity financing and non-dilutive capital from collaboration partners to ensure that CAMP4 is well-capitalized to achieve its goals.” Corporate Highlights: Presented compelling preclinical data for SYNGAP1 program showing that haploinsufficient SYNGAP1 mice treated with CMP-002 demonstrated an increase in SYNGAP1 protein levels and that treatment rescued multiple SYNGAP1-dependent behavioral phenotypes. This data further demonstrated that CMP-002 administration led to a significant increase in SYNGAP1 protein levels in relevant brain regions in non-human primates (NHPs).Initiated GLP toxicology studies for CMP-002 in support of future clinical trial applications, which could enable initiation of a global Phase 1/2 clinical trial in patients as early as H2 2026.Entered a strategic research, collaboration, and license agreement with GSK to identify and develop antisense nucleotide (ASO) drug candidates for multiple gene targets relevant to neurodegenerative and kidney disease indications. CAMP4 received a $17.5 million cash upfront payment and has the potential to receive up to $440 million upon achievement of certain development and commercial milestones, in addition to tiered royalties on future product sales.Completed oversubscribed private placement for gross proceeds of up to $100 million, $50 million of which was received in the form of an upfront payment in September, as well as underwritten offering of common stock with gross proceeds of $30 million in December to fund further development of CMP-002.Conducted analysis from single ascending dose (SAD) and multiple ascending dose (MAD) portions of the CMP-001 Phase 1 clinical trial and made strategic decision to pause further investment in the development of CMP-001 and explore potential partnership opportunities. Full Year 2025 Financial Results Cash and cash equivalents as of December 31, 2025, were $109.5 million, compared to $64.0 million as of December 31, 2024. The Company believes that its current cash and cash equivalents will be sufficient to fund its planned activities into 2028. R&D Expenses: Research and development (“R&D”) expenses for the year ended December 31, 2025, were $38.2 million, compared to $38.8 million for the year ended December 31, 2024. The decrease was primarily driven by a gain on lease modification and decreased clinical costs associated with CMP-001. G&A Expenses: General and administrative (“G&A”) expenses were $17.4 million for the year ended December 31, 2025, compared to $14.9 million for the year ended December 31, 2024. The change was primarily driven by an increase in professional expenses. Net Loss: Net loss for the year ended December 31, 2025, was $80.4 million compared to $51.8 million for the year ended December 31, 2024. The increase in net loss was primarily driven by a $29.8 million non-cash loss recognized due to a change in fair value of the derivative tranche liability related to our September private placement. About CAMP4 Therapeutics CAMP4 is developing disease-modifying treatments for a broad range of genetic diseases where amplifying healthy protein may offer therapeutic benefits. Our approach amplifies mRNA by harnessing a fundamental mechanism of how genes are controlled. To amplify mRNA, our therapeutic ASO drug candidates target regulatory RNAs (regRNAs), which act locally on transcription factors and are the master regulators of gene expression. CAMP4’s proprietary RAP Platform™ enables the mapping of regRNAs and generation of therapeutic candidates designed to target the regRNAs associated with genes underlying haploinsufficient and recessive partial loss-of-function disorders, of which there are more than 1,200, in which a modest increase in protein expression may have the potential to be clinically meaningful. For more information, visit camp4tx.com. Forward-Looking Statements This press release contains forward-looking statements which involve risks, uncertainties and contingencies, many of which are beyond the control of the Company, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. All statements other than statements of historical facts contained in this press release are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements include, but are not limited to, statements concerning the anticipated timing to advance the Company’s SYNGAP1 program into a clinical trial; the Company’s plan to pursue partnership opportunities to support the further development of CMP-001; the development of ASO drug candidates for multiple gene targets relevant to neurodegenerative and kidney disease indications; the potential of the Company’s platform technology; the Company’s receipt of future contingent milestones and/or royalties; the potential to receive up to $50 million in additional gross proceeds in connection with the Company’s September 2025 private placement; the Company’s strategy, goals, business plans and focus; the therapeutic potential of the Company’s product candidates; and the Company’s cash runway guidance. The forward-looking statements in this press release speak only as of the date of this press release and are subject to a number of known and unknown risks, uncertainties and assumptions that could cause the Company’s actual results to differ materially from those anticipated in the forward-looking statements, including, but not limited to: the Company’s limited operating history, incurrence of substantial losses since the Company’s inception and anticipation of incurring substantial and increasing losses for the foreseeable future; the Company’s need for substantial additional financing to achieve the Company’s goals; the uncertainty of clinical development, which is lengthy and expensive, and characterized by uncertain outcomes, and risks related to additional costs or delays in completing, or failing to complete, the development and commercialization of the Company’s current product candidates or any future product candidates; delays or difficulties in the enrollment and dosing of patients in clinical trials; the impact of any significant adverse events or undesirable side effects caused by the Company’s product candidates; potential competition, including from large and specialty pharmaceutical and biotechnology companies; the Company’s ability to realize the benefits of the Company’s current or future collaborations or licensing arrangements and ability to successfully consummate future partnerships; the Company’s ability to obtain regulatory approval to commercialize any product candidate in the United States or any other jurisdiction, and the risk that any such approval may be for a more narrow indication than the Company seeks; the Company’s dependence on the services of the Company’s senior management and other clinical and scientific personnel, and the Company’s ability to retain these individuals or recruit additional management or clinical and scientific personnel; the Company’s ability to grow the Company’s organization, and manage the Company’s growth and expansion of the Company’s operations; risks related to the manufacturing of the Company’s product candidates, which is complex, and the risk that the Company’s third-party manufacturers may encounter difficulties in production; the Company’s ability to obtain and maintain sufficient intellectual property protection for the Company’s product candidates or any future product candidates the Company may develop; the Company’s reliance on third parties to conduct the Company’s preclinical studies and clinical trials; the Company’s compliance with the Company’s obligations under the licenses granted to the Company by others, for the rights to develop and commercialize the Company’s product candidates; risks related to the operations of the Company’s suppliers; and other risks and uncertainties described in the section “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, as well as other information the Company files with the Securities and Exchange Commission. The forward-looking statements in this press release are inherently uncertain and are not guarantees of future events. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond the Company’s control, you should not unduly rely on these forward-looking statements. The events and circumstances reflected in the forward-looking statements may not be achieved or occur and actual future results, levels of activity, performance and events and circumstances could differ materially from those projected in the forward-looking statements. Moreover, the Company operates in an evolving environment. New risks and uncertainties may emerge from time to time, and management cannot predict all risks and uncertainties. Investors, potential investors, and others should give careful consideration to these risks and uncertainties. Except as required by applicable law, the Company does not undertake to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. Contacts Investor Relations: Sara Michelmore Milestone Advisors [email protected] Media: Sofia Bermudez LifeSci Communications [email protected] CAMP4 Therapeutics Corporation Consolidated Statements of Operations and Comprehensive Loss (In thousands, except for share and per share data) Year ended December 31, 2025 2024 Revenue Research and collaboration revenue$3,498 $652 Operating expenses Research and development 38,202 38,817 General and administrative 17,357 14,923 Impairment of right-of-use asset 494 — Total operating expenses 56,053 53,740 Loss from operations (52,555) (53,088)Other (expense) income, net: Interest income 2,174 1,330 Change in fair value of derivative tranche liability (29,830) — Other expense (192) (33)Total other (expense) income, net (27,848) 1,297 Net loss$(80,403) $(51,791)Net loss per share attributable to common stockholders, basic and diluted$(2.65) $(11.04)Weighted average shares of common stock outstanding, basic and diluted 30,380,567 4,690,094 December 31,Condensed Balance Sheet Data 2025 2024 (in thousands) Cash and cash equivalents$109,517 $64,039 Working capital(1)98,581 56,785 Total assets 117,808 78,307 Total liabilities 70,104 15,163 Accumulated deficit (292,156) (211,753)Total stockholders' equity 47,704 63,144 (1) Working capital is defined as total current assets less total current liabilities. See our consolidated financial statements and the related notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2025, for further details regarding our current assets and current liabilities.
	2026-03-05 21:06 6d ago	2026-03-05 16:05 6d ago	Texas Roadhouse, Inc. Appoints Lisa Ingram to Board of Directors	stocknewsapi	MHO TXRH
March 05, 2026 16:05 ET \| Source: Texas Roadhouse, Inc LOUISVILLE, Ky., March 05, 2026 (GLOBE NEWSWIRE) -- Texas Roadhouse, Inc. (Nasdaq: TXRH) announced today that Lisa Ingram has been appointed to the Company’s Board of Directors. Ms. Ingram is the Chief Executive Officer and Chair of the Board of Directors for White Castle System, Inc., which is based in Columbus, Ohio. White Castle currently has 340 restaurants in 14 states. In addition, the company owns and operates 6 manufacturing plants that supply products to its restaurants and its consumer product goods, which are sold in grocery stores in all 50 states. Known as the “Slider Queen,” Ingram has led White Castle since 2015 and is the fourth-generation family member to lead the iconic 105-year-old brand, which is considered to be the nation’s first fast-food hamburger chain. Jerry Morgan, Texas Roadhouse Chief Executive Officer and Executive Vice Chairman of the Board commented, “We are excited to have Lisa join our Board of Directors. Lisa literally grew up in the restaurant business and knows what it takes to lead a highly successful, and founder-inspired company. She also understands the importance of being a people-first business. There’s no doubt Lisa will bring incredible value to our company.” Ms. Ingram received her Bachelor of Business Administration from Southern Methodist University and her MBA from Ohio State University. In addition to her role as CEO, Lisa is active in the Columbus community. She currently serves as the Chair of the Board of OhioHealth and serves on the board of M/I Homes (NYSE:MHO). About Texas Roadhouse Texas Roadhouse, Inc. is a growing restaurant company operating predominantly in the casual dining segment that first opened in 1993 and today has grown to over 820 restaurants system-wide in 49 states, one U.S. territory, and ten foreign countries. For more information, please visit the Company’s Web site at www.texasroadhouse.com. Contacts: Investor Relations Michael Bailen (502) 515-7298 Media Megan Pence (502) 461-1878
	2026-03-05 21:06 6d ago	2026-03-05 16:05 6d ago	Nyxoah to Release Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026	stocknewsapi	NYXH
Nyxoah to Release Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026 Mont-Saint-Guibert, Belgium – March 5 2026, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced that the Company will release financial results for the fourth quarter and full year of 2025 on Thursday, March 19, 2026. Company management will host a conference call to discuss financial results that day beginning at 10:30pm CET / 4:30pm ET. A webcast of the call will be accessible via the Investor Relations page of the Nyxoah website or through this link: Nyxoah's Q4 and FY 2025 Earnings Call Webcast. For those not planning to ask a question of management, the Company recommends listening via the webcast. If you plan to ask a question, please use the following link: Nyxoah's Q4 and FY 2025 Earnings Call . After registering, an email will be sent, including dial-in details and a unique conference call access code required to join the live call. To ensure you are connected prior to the beginning of the call, the Company suggests registering a minimum of 10 minutes before the start of the call. The archived webcast will be available for replay shortly after the close of the call. About Nyxoah Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat OSA. Nyxoah’s lead solution is the Genio system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest. Following the successful completion of the BLAST OSA study, the Genio system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company announced positive outcomes from the DREAM IDE pivotal study and receipt of approval from the FDA for a subset of adult patients with moderate to severe OSA with an AHI of greater than or equal to 15 and less than or equal to 65. For more information, please visit http://www.nyxoah.com/. Caution – CE marked since 2019. FDA approved in August 2025 as prescription-only device. Forward-looking statements Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company’s or, as appropriate, the Company directors’ or management’s current expectations regarding the Genio system; the potential advantages of the Genio system; Nyxoah’s goals with respect to the potential use of the Genio system; the Company's commercialization strategy and entrance to the U.S. market; the Company's results of operations, financial condition, liquidity, performance, prospects, growth, future revenue and strategies. By their nature, forward-looking statements involve a number of risks, uncertainties, assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. These risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the “Risk Factors” section of the Company’s Annual Report on Form 20-F for the year ended December 31, 2024, filed with the Securities and Exchange Commission (“SEC”) on March 20, 2025 and subsequent reports that the Company files with the SEC. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward-looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition, even if actual results or developments are consistent with the forward-looking statements contained in this press release, those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward-looking statements. As a result, the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward- looking statements are based, except if specifically required to do so by law or regulation. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release. Contacts: Nyxoah John Landry, CFO [email protected] Rémi Renard Head of Investor Relations & Corporate Communication [email protected] ENGLISH_4Q&FY25 Earnings Call Announcement
	2026-03-05 20:06 6d ago	2026-03-05 14:39 6d ago	MWC 2026 \| Fibocom Unveils 5G MiFi Solution Based on Linux OS and Qualcomm QMB415 Platform	stocknewsapi	QCOM
, /PRNewswire/ -- On March 5, Fibocom officially launched the FG205 module and 5G MiFi solution based on the Qualcomm QMB415 platform. The QMB415 platform supports the Linux operating system and, with its deeply customized hardware architecture and reduced memory requirements, delivers an optimized solution and more reliable supply stability for wireless broadband applications. Deep Hardware Customization: Simplifying Design for Core MiFi Needs The FG205 module and 5G MiFi solution based on the Qualcomm QMB415 platform debuted at MWC 2026 Built on the Qualcomm SM4450 chipset, the QMB415 platform has been highly customized for wireless broadband scenarios. Unlike traditional smartphone chip platforms that often include redundant features, this solution adopts a streamlined architecture: reducing unnecessary CPU computing power and removing the GPU to focus on network connectivity performance. Software System: Linux OS Eliminates "Memory Anxiety" A key highlight of Fibocom's newly released MiFi solution is its support for the Linux operating system. Previously, most 5G SoC platforms used Android, which typically requires larger memory capacity (usually ≥3GB). After adapting to Linux OS, the memory requirement of this solution can be as low as 1GB. This reduced storage configuration not only achieves a lower cost but also minimizes supply and price risks associated with memory components. Platform Evolution: Pin-to-Pin Compatibility for Rapid Iteration To help customers shorten time-to-market, the solution ensures hardware design continuity. The FG205 module based on the QMB415 platform maintains the same form factor and layout as Fibocom's FG180/190 series modules based on the Snapdragon X72/X75 platform. With pin-to-pin compatibility, device manufacturers can switch between different performance tiers on the same hardware platform without redesigning the PCB, enabling faster product upgrades and iterations. For Wi-Fi integration, Fibocom will introduce multiple configurations for the FG205 solution supporting Wi-Fi 5, Wi-Fi 6, Wi-Fi 6E, and Wi-Fi 7, further expanding its MBB product portfolio and meeting diverse customer requirements with cost-efficient and reliable wireless broadband solutions. About Fibocom Fibocom, founded in 1999, is China's first wireless communication module company listed on both the A-share and H-share markets (300638.SZ, 0638.HK). As a global leading provider of wireless communication modules and AI solutions, Fibocom leverages wireless communication and artificial intelligence as its core technologies to provide integrated hardware and software solutions that empower industry applications. These solutions accelerate the transformation from "Connect Everything" to "Intelligent Connectivity" across diverse industries. Fibocom's one-stop solutions encompass cellular communication, AI, automotive, and GNSS modules, as well as AI toolchains, supporting industry-side and mainstream large model integration, and providing AI Agent, global connectivity, and cloud services, driving the digital intelligence upgrades in industries such as robotics, consumer electronics, low-altitude economy, intelligent transportation, smart retail, and smart energy. SOURCE Fibocom Wireless Inc.
	2026-03-05 20:06 6d ago	2026-03-05 14:41 6d ago	Day One Biopharmaceuticals: 'Strong Buy,' Several 2026 Milestones In Play Plus OJEMDA Growth	stocknewsapi	DAWN
Day One Biopharmaceuticals is maintained at a "Strong Buy" rating, driven by robust pipeline progress and multiple upcoming catalysts. The company's OJEMDA achieved FDA approval and delivered 172% year-over-year revenue growth in 2025, with label expansion efforts underway in pivotal phase 3 trial. Two novel ADC programs, Emi-Le and DAY-301, target high-value oncology indications, with key clinical data readouts expected in mid- and late 2026.
	2026-03-05 20:06 6d ago	2026-03-05 14:41 6d ago	Oracle to cut thousands of jobs amid AI data center spending push, Bloomberg reports	stocknewsapi	ORCL
Oracle Corp (NYSE:ORCL, XETRA:ORC) is planning to cut thousands of jobs as it works to manage the financial strain from a major expansion of artificial intelligence data centers, according to a report by Bloomberg. The layoffs are expected to affect multiple divisions and could begin as soon as this month. Some of the reductions will target roles the company believes will become less necessary as artificial intelligence is increasingly integrated into its operations. The cuts are expected to be broader than Oracle’s usual rolling layoffs. The company has also started reviewing open job listings within its cloud unit, effectively slowing or freezing some hiring as it reassesses staffing needs. Oracle, traditionally known for its database software, has been ramping up investment in cloud computing and AI infrastructure in recent years. The push is part of its strategy to compete more directly with industry leaders Amazon.com Inc (NASDAQ:AMZN) and Microsoft Corp (NASDAQ:MSFT). However, the heavy spending required to build new data centers is expected to pressure the company’s finances. Wall Street analysts project that these investments could push Oracle’s cash flow into negative territory for several years before the spending begins to generate returns around 2030. Last month, Oracle said it could raise up to $50 billion this year through a mix of debt and equity to help fund its AI-driven expansion.
	2026-03-05 20:06 6d ago	2026-03-05 14:42 6d ago	FDA official calls UniQure's gene therapy a 'failed' treatment for Huntington's disease	stocknewsapi	QURE
UniQure needs to run another study to prove that its gene therapy "actually helps people with Huntington's disease," a senior U.S. Food and Drug Administration official said on a call with reporters Thursday. The official, who requested anonymity before discussing sensitive information, confirmed the agency has asked the company to run a placebo controlled trial of its treatment, which is administered directly into the brain. UniQure has said that type of study isn't ethical because it would require putting people under general anesthesia for hours, a characterization the official disputed. "So what is really going on? UniQure is the latest company to make a failed therapy for Huntington's patients," the official said. "They likely acknowledge or understand at some deep level that their trial failed years ago, and instead of doing the right thing and running the correct clinical study, UniQure is performing a distorted or manipulated comparison in the mind of FDA." The comments mark the latest development in a messy public spat between UniQure and the FDA, and as the agency comes under fire for a number of recent drug approval application rejections, including some where companies have accused it of going back on previous guidance. FDA Commissioner Marty Makary in an interview with CNBC's Becky Quick last week seemingly criticized UniQure's gene therapy for Huntington's disease. Makary didn't name UniQure but described its treatment. watch now UniQure then accused the FDA of reversing its stance that the company's clinical trial data would be sufficient to seek approval. UniQure's study used an outside database to measure how patients with Huntington's disease might decline without treatment, known as an external control. UniQure has said it wouldn't be feasible to run a true randomized, double-blind placebo-controlled study, considered the gold standard, because it wouldn't be ethical to make people undergo a sham hours-long brain surgery. The FDA official said the agency "never agreed to accept this distorted comparison" and the FDA "never makes such assurances." Instead, the "FDA will always say, 'Well, we have to see the data when we get it.'" UniQure didn't immediately comment. The company's stock rose more than 10% on Thursday and has fallen 58% this year as of Thursday afternoon.
	2026-03-05 20:06 6d ago	2026-03-05 14:45 6d ago	CRWV 8-DAY DEADLINE ALERT: Hagens Berman Analyzes CoreWeave (CRWV) $452M Q4 Loss and Soft Guidance Amid Ongoing Securities Fraud Litigation	stocknewsapi	CRWV
Q4 Net Loss Nearly Doubles Estimates; Firm Reminds Investors of March 13 Lead Plaintiff Deadline , /PRNewswire/ -- National shareholder rights law firm Hagens Berman provides an update to investors in CoreWeave, Inc. (NASDAQ: CRWV) following the company's dismal fourth-quarter 2025 financial results. The news follows allegations that the company concealed operational failures, as pled in a recently filed securities class action. Hagens Berman is investigating the alleged claims in the pending suit. The firm urges investors who suffered substantial losses to: SUBMIT YOUR LOSSES NOW On February 26, 2026, CoreWeave reported a Q4 net loss of $452 million, or $0.89 per share—a staggering figure that nearly doubled the $0.49 loss per share anticipated by Wall Street analysts. Compounding the miss, CoreWeave issued a soft Q1 2026 revenue guidance of $1.9 billion to $2.0 billion, falling significantly short of the $2.3 billion consensus. On this news, CRWV shares plunged nearly 20%. The disappointing Q4 results come after the filing of a securities class action suit against CoreWeave and certain of its executives arising from the company's inability to scale its high-performance computing (HPC) clusters at the pace allegedly promised. "We are investigating whether the company overstated scaling capabilities and hid critical delays," said Reed Kathrein, the Hagens Berman partner leading the firm's investigation of the pending claims. View our latest video summary of the allegations: youtube.com/watch?v=rWaDX1uGyJs The CoreWeave, Inc. (CRWV) Securities Class Action The pending securities class action, Masaitis v. CoreWeave, Inc., et al., No. 2:26-cv-00355, filed in the U.S. District Court for the District of New Jersey, seeks to recover losses for investors who acquired CoreWeave securities between March 28, 2025, and December 15, 2025 (the "Class Period"). The complaint alleges that CoreWeave and its executives violated the Securities Exchange Act of 1934 by: Overstating Scaling Capabilities: Allegedly misrepresenting the company's ability to satisfy "unprecedented" demand for its NVIDIA-powered AI cloud. Concealing Critical Delays: Failing to disclose that the Denton, Texas data center cluster—intended to service OpenAI—was months behind schedule due to weather and design plan revisions. Single-Supplier Dependency: Understating the operational and financial risks of its heavy reliance on a single third-party data center developer. Share Price Erosion: Since these infrastructure failures began to surface in late 2025, CoreWeave's stock has faced severe downward pressure, further exacerbated by the latest Q4 earnings shock. Critical Deadline: March 13, 2026 If you purchased CoreWeave common stock during the Class Period (Mar. 28, 2025 – Dec. 15, 2025) and suffered substantial losses, you have until March 13, 2026, to ask the Court to appoint you as Lead Plaintiff. TO SUBMIT YOUR COREWEAVE (CRWV) INVESTMENT LOSSES NOW, PLEASE USE THE SECURE FORM BELOW: Report your CRWV Investment Losses to Hagens Berman Now If you'd like more information and answers to frequently asked questions about the CoreWeave case and our investigation, read more » Whistleblowers: Persons with non-public information regarding CoreWeave should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected]. About Hagens Berman Hagens Berman is a global plaintiffs' rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman's team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw. SOURCE Hagens Berman Sobol Shapiro LLP
	2026-03-05 20:06 6d ago	2026-03-05 14:45 6d ago	5 Best Dividend Stocks To Combine Growth, Income, And Defense In 2026	stocknewsapi	DELL LMT NEM PINE PM
HomeStock IdeasQuick Picks & Lists SummaryPeriods of persistent inflation, higher interest rates, and geopolitical tension can create a challenging environment for investors.Companies that can provide a defensive and diversified mix in this macro backdrop, including hard assets, resilient consumer demand, income-generating real estate, and tech infrastructure.By combining reliable dividends backed by outstanding profitability, five companies illustrate how investors can build portfolios that can withstand volatility while maintaining exposure to potential upside in 2026.I am Steven Cress, Head of Quantitative Strategies at Seeking Alpha. I manage the quant ratings and factor grades on stocks and ETFs in Seeking Alpha Premium. I also lead Alpha Picks, which selects the two most attractive stocks to buy each month, and also determines when to sell them. Olivier Le Moal/iStock via Getty Images Dividend Stocks That Can Thrive in a Challenging 2026 Macro Backdrop Investors entered 2026 expecting inflation to moderate, interest rates to gradually fall, and geopolitical tensions to remain modestly high but contained. However, reality has presented a more challenging set of circumstances. A resilient labor 87.38K Followers Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it. I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given that any particular security, portfolio, transaction or investment strategy is suitable for any specific person. The author is not advising you personally concerning the nature, potential, value or suitability of any particular security or other matter. You alone are solely responsible for determining whether any investment, security or strategy, or any product or service, is appropriate or suitable for you based on your investment objectives and personal and financial situation. Steven Cress is the Head of Quantitative Strategy at Seeking Alpha. Any views or opinions expressed herein may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank.
	2026-03-05 20:06 6d ago	2026-03-05 14:45 6d ago	Ituran Location and Control Ltd. (ITRN) Q4 2025 Earnings Call Transcript	stocknewsapi	ITRN
Ituran Location and Control Ltd. (ITRN) Q4 2025 Earnings Call Transcript
	2026-03-05 20:06 6d ago	2026-03-05 14:45 6d ago	Permanent TSB Group Holdings plc (ILPMY) Q4 2025 Earnings Call Transcript	stocknewsapi	ILPMY
Permanent TSB Group Holdings plc (ILPMY) Q4 2025 Earnings Call Transcript
	2026-03-05 20:06 6d ago	2026-03-05 14:46 6d ago	Viemed Healthcare, Inc. (VMD) Q4 2025 Earnings Call Transcript	stocknewsapi	VMD
Viemed Healthcare, Inc. (VMD) Q4 2025 Earnings Call Transcript
	2026-03-05 20:06 6d ago	2026-03-05 14:46 6d ago	Varonis Systems, Inc. (VRNS) Presents at Morgan Stanley Technology, Media & Telecom Conference 2026 Transcript	stocknewsapi	VRNS
Varonis Systems, Inc. (VRNS) Morgan Stanley Technology, Media & Telecom Conference 2026 March 5, 2026 12:15 PM EST Company Participants Brian Vecci - Field C.T.O Guy Melamed - CFO & COO Conference Call Participants Meta Marshall - Morgan Stanley, Research Division Presentation Meta Marshall Morgan Stanley, Research Division All right. Welcome, everybody. While we get situated, I'll read the disclosures real quick. For important disclosures, please see the Morgan Stanley research disclosure website at morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative. I'm Meta Marshall. I cover cybersecurity here at Morgan Stanley. We're delighted to have Varonis, Guy Melamed, CFO; Brian Vecci, CTO. Question-and-Answer Session Meta Marshall Morgan Stanley, Research Division All right. Perfect. Maybe just to kind of start with in terms of -- just those who are kind of less familiar with Varonis or kind of data security in general, just kind of giving an overview of the company. Brian Vecci Field C.T.O So where I'd start is almost all aspects of cybersecurity touches on data. Nobody breaks into a bank to steal the pens, they're after money. Nobody gets access to an account, an identity, an API these days, an agent, your infrastructure unless they're really after data. Companies face when it comes to data because they have so much not just in data centers these days, but in various cloud platforms, all of the hyperscalers, the applications, all of the AI workloads that they're building. They face a lot of regulatory risk. What do I have? Where is it? Are all the right controls in place, a lot of reputational risk. They don't want to be on the front page of the Wall Street Journal because they got breached. And they need to do more with less. They need to
	2026-03-05 20:06 6d ago	2026-03-05 14:46 6d ago	Ellington Credit Company (EARN) Q4 2025 Earnings Call Transcript	stocknewsapi	EARN
Ellington Credit Company (EARN) Q4 2025 Earnings Call Transcript
	2026-03-05 20:06 6d ago	2026-03-05 14:46 6d ago	Endeavour Mining plc (EDV:CA) Q4 2025 Earnings Call Transcript	stocknewsapi	EDV EDVMF
Q4: 2026-03-05 Earnings SummaryEPS of $1.27 beats by $0.09 \| Revenue of $1.74B (28.39% Y/Y) beats by $69.23M Endeavour Mining plc (EDV:CA) Q4 2025 Earnings Call March 5, 2026 8:30 AM EST Company Participants Jack Garman - Vice President of Investor Relations Ian Cockerill - CEO & Executive Director Guy Young - Executive VP & CFO Djaria Traore - Executive Vice President of Operations & ESG Conference Call Participants Alain Gabriel - Morgan Stanley, Research Division Ovais Habib - Scotiabank Global Banking and Markets, Research Division Fahad Tariq - Jefferies LLC, Research Division Marina Calero Ródenas - RBC Capital Markets, Research Division Frederic Bolton - BMO Capital Markets Equity Research Mohamed Sidibe - National Bank Financial, Inc., Research Division Daniel Major - UBS Investment Bank, Research Division Presentation Operator Good day, and thank you for standing by. Welcome to Endeavour Mining's Fourth Quarter and Full Year 2025 Results Webcast. [Operator Instructions] Today's conference call is being recorded, and a transcript of the call will be available on Endeavour's website tomorrow. I would now like to hand the call over to Endeavour's Vice President of Investor Relations, Jack Garman. Please go ahead. Jack Garman Vice President of Investor Relations Hello, everyone, and welcome to Endeavour's Q4 and Full Year 2025 Results Webcast. Before we start, please note our usual disclaimer. On the call today, I'm delighted to be joined by Ian Cockerill, Chief Executive Officer; Guy Young, Chief Financial Officer; and Djaria Traore, Executive Vice President of Operations and ESG. Today's call will follow our usual format. Ian will first go through the highlights of the quarter and the year, Guy will present the financials, and Djaria will walk through our operating results by mine before handing back to Ian for his closing remarks. We'll then open the line up for questions. With that, I'll now hand over to Ian. Ian Cockerill CEO & Executive Director Thank you, Jack, and hello to everyone who's joining us on the
	2026-03-05 20:06 6d ago	2026-03-05 14:46 6d ago	GitLab Inc. (GTLB) Presents at Morgan Stanley Technology, Media & Telecom Conference 2026 Transcript	stocknewsapi	GTLB
GitLab Inc. (GTLB) Presents at Morgan Stanley Technology, Media & Telecom Conference 2026 Transcript
	2026-03-05 20:06 6d ago	2026-03-05 14:49 6d ago	Coda Octopus Group Sets Fiscal First Quarter 2026 Earnings Conference Call for Tuesday, March 17, 2026, at 10 a.m. Eastern Time	stocknewsapi	CODA
Orlando, FL, March 05, 2026 (GLOBE NEWSWIRE) -- Coda Octopus Group, Inc. (“CODA” or the “Company”) (NASDAQ: CODA), a global market leader in real-time 3D/4D/5D and 6D imaging sonar technology for real-time subsea intelligence and new generation augmented reality diving technology (“DAVD”), will host a conference call on Tuesday, March 17, 2026 at 10:00 a.m. Eastern time to discuss its results for its Fiscal First Quarter 2026 ended January 31, 2026 (“FQ2026”). A press release detailing these results will be issued before the opening of trading on March 17, 2026. The Company’s management will provide prepared remarks, followed by a question-and-answer period. Date: Tuesday, March 17, 2026 Time: 10:00 a.m. Eastern time (7:00 a.m. Pacific time) U.S. dial-in numbers: 1-877-451-6152 or 1-201-389-0879 International number: 1-201-389-0879 Conference ID: 13758973 The conference call will broadcast live and be available for replay here. Persons interested in attending are required to call the conference telephone number approximately 10 minutes before the start time. An operator will register your name and organization. If you have any difficulty connecting with the conference call, please press *0. A replay of the call will be available after approximately 2:00 p.m. Eastern time on the same day through Tuesday, March 31, 2026 at 11:59 p.m. ET. Telephone replay numbers: 1-844-512-2921 or 1-412-317-6671 International replay number: 1-412-317-6671 Access ID: 13758973 About Coda Octopus Group, Inc. The Company, founded in 1994, is an established supplier to the underwater/subsea market. It supplies a range of hardware and software solutions which includes key proprietary real time 4D/5D/6D imaging sonars, marketed under the name Echoscope®, Echoscope PIPE® and Echoscope PIPE NANO Gen Series® addressing the underwater imaging sensor market along with new generation diving technology, known as the Diver Augmented Vision Display (“DAVD”) system. The Company’s Echoscope PIPE® sonar generates real-time 3D/4D/5D images of moving objects underwater including in zero visibility water conditions. Echoscope technology is used globally for numerous applications in both the commercial offshore market and defense underwater markets. Applications for the Echoscope® technology include complex mapping underwater, subsea intervention, subsea asset placements, salvage and recovery, search and rescue, offshore renewables cable installations and surveys, marine construction, subsea infrastructure installation, mining applications, robotics (3D Perception and Depth), breakwater construction and monitoring, decommissioning, diving applications and port and harbor security. The recently launched new generation of diving technology, DAVD, has the potential to change the way global diving operations are performed (both in the Defense and Commercial space) because it is a fully integrated singular system for topside control and fully connected diver HUD system, allowing both the topside and diver to share a range of critical information and visualize the same underwater scene. Furthermore, the DAVD integrates the Company’s sonar technology, which allows dive operations to be performed in zero visibility conditions, a common problem that besets these operations. The Company also includes two discrete Defense Engineering Services businesses Coda Octopus Martech Ltd (UK based) and Coda Octopus Engineering, Inc. (US based) whose primary business model is to supply sub-assemblies into broader mission critical programs in the capacity of sub-contractors to the Prime Defense Contractors. Their scope of supply under these programs typically includes concept, design, prototype, manufacturing, and post-sale support. This gives them the opportunity to have repeat orders for these sub-assemblies through the life of these programs. The Company recently acquired Precision Acoustics Limited, an acoustics sensor and materials business. PAL is a supplier of acoustic sensors and materials. PAL also performs calibration services for medical devices and is accredited to ISO/IEC 17025 standard. PAL is one of only two organizations in the United Kingdom with this certification, alongside the National Physical Laboratory (NPL). Globally, only a handful of facilities hold ISO/IEC 17025 accreditation for these measurements. Ultrasonic free-field sensitivity calibration is critical for markets that require precision ultrasonic measurement, strict safety compliance, and full metrological traceability. These include regulated and high-risk applications, such as diagnostic and therapeutic medical ultrasound and defense and underwater acoustics, where free-field calibration is essential to ensure accurate beam sensitivity and minimal interference. PAL’s operations are based in the United Kingdom. For further information, please visit http://www.codaoctopusgroup.com or contact us at [email protected]. Forward Looking Statements This press release contains forward-looking statements concerning Coda Octopus Group, Inc. within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. When used in this document, the words “may”, “would”, “could”, “will”, “intend”, “plan”, “anticipate”, “believe”, “estimate”, “expect”, “assume” and similar expressions are intended to identify forward‐looking statements. Those forward-looking statements include, without limitation, statements regarding the Company's expectations for the growth of the Company's operations and revenue. Such statements are subject to certain risks and uncertainties, and actual circumstances, events or results may differ materially from those projected in such forward-looking statements. Factors that could cause or contribute to differences include, but are not limited to, fluctuations in foreign exchange rates, changes in global economic condition, tariff and trade policies, reduction in government spending in the Defense Sector, customer demand, geopolitical issues, the outcome of our ongoing research and development efforts relating to our products including our patented real time 3D solutions or DAVD; our ability to develop the sales force required to achieve our development and other examples of forward looking statement set forth in our Annual Report on Form 10-K for the year ended October 31, 2025, filed with the Securities and Exchange Commission on January 29, 2026 as amended on our Form 10-K/A, filed with the Securities and Exchange Commission on February 26, 2026. Coda Octopus Group, Inc., does not undertake and specifically disclaims any obligation to update or revise such statements to reflect new circumstances or unanticipated events as they occur. Contact: Mr. Dillon King Coda Octopus IR Team at [email protected] Coda Octopus Group, Inc. 1- 407-735-2406
	2026-03-05 20:06 6d ago	2026-03-05 14:49 6d ago	SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Texas Mineral Resources Corp. (OTCQB: TMRC)	stocknewsapi	TMRC
, /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Texas Mineral Resources Corp. (OTCQB: TMRC) related to its sale to USA Rare Earth, Inc. for 3,823,328 shares of USA Rare Earth common stock. Is it a fair deal? Click here for more info https://monteverdelaw.com/case/texas-mineral-resources-corp/. It is free and there is no cost or obligation to you. NOT ALL LAW FIRMS ARE EQUAL. Before you hire a law firm, you should talk to a lawyer and ask: Do you file class actions and go to Court? When was the last time you recovered money for shareholders? What cases did you recover money in and how much? About Monteverde & Associates PC Our firm litigates and has recovered money for shareholders…and we do it from our offices in the Empire State Building. We are a national class action securities firm with a successful track record in trial and appellate courts, including the U.S. Supreme Court. No one is above the law. If you own common stock in the above listed company and have concerns or wish to obtain additional information free of charge, please visit our website or contact Juan Monteverde, Esq. either via e-mail at [email protected] or by telephone at (212) 971-1341. Contact: Juan Monteverde, Esq. MONTEVERDE & ASSOCIATES PC The Empire State Building 350 Fifth Ave. Suite 4740 New York, NY 10118 United States of America [email protected] Tel: (212) 971-1341 Attorney Advertising. (C) 2026 Monteverde & Associates PC. The law firm responsible for this advertisement is Monteverde & Associates PC (www.monteverdelaw.com). Prior results do not guarantee a similar outcome with respect to any future matter. SOURCE Monteverde & Associates PC
	2026-03-05 20:06 6d ago	2026-03-05 14:49 6d ago	SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Farmer Brothers Co. (NASDAQ: FARM)	stocknewsapi	FARM
, /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Farmer Brothers Co. (NASDAQ: FARM) related to its sale to Royal Cup, Inc. Under the terms of the proposed transaction, Farmer shareholders are expected to receive $1.29 per share in cash. Is it a fair deal? Click here for more info https://monteverdelaw.com/case/farmer-brothers-co/. It is free and there is no cost or obligation to you. NOT ALL LAW FIRMS ARE EQUAL. Before you hire a law firm, you should talk to a lawyer and ask: Do you file class actions and go to Court? When was the last time you recovered money for shareholders? What cases did you recover money in and how much? About Monteverde & Associates PC Our firm litigates and has recovered money for shareholders…and we do it from our offices in the Empire State Building. We are a national class action securities firm with a successful track record in trial and appellate courts, including the U.S. Supreme Court. No one is above the law. If you own common stock in the above listed company and have concerns or wish to obtain additional information free of charge, please visit our website or contact Juan Monteverde, Esq. either via e-mail at [email protected] or by telephone at (212) 971-1341. Contact: Juan Monteverde, Esq. MONTEVERDE & ASSOCIATES PC The Empire State Building 350 Fifth Ave. Suite 4740 New York, NY 10118 United States of America [email protected] Tel: (212) 971-1341 Attorney Advertising. (C) 2026 Monteverde & Associates PC. The law firm responsible for this advertisement is Monteverde & Associates PC (www.monteverdelaw.com). Prior results do not guarantee a similar outcome with respect to any future matter. SOURCE Monteverde & Associates PC
	2026-03-05 20:06 6d ago	2026-03-05 14:49 6d ago	Suntex Enterprises Signs Letter of Intent to Acquire Deep South Electrical Contractors and GoldenEra Development from Golden Triangle Ventures	stocknewsapi	SNTX
AUSTIN, Texas, March 05, 2026 (GLOBE NEWSWIRE) -- via IBN – Suntex Enterprises, Inc. (OTC: SNTX) today announced that it has executed a Letter of Intent (LOI) to acquire Deep South Electrical Contractors and GoldenEra Development, two operating subsidiaries currently held by Golden Triangle Ventures, Inc. The agreement outlines Suntex’s intent to bring both operating businesses under the Suntex corporate structure, further expanding the Company’s operating footprint across infrastructure, construction services, and development operations. Deep South Electrical Contractors is an active commercial and industrial electrical contractor supporting large-scale infrastructure and technology-driven facilities. GoldenEra Development provides construction management and development services tied to commercial and industrial projects. Both businesses are currently operating and engaged on projects supporting continued growth. Management believes the addition of these operating companies will significantly strengthen Suntex’s revenue base and expand its ability to pursue larger infrastructure and development opportunities. “This agreement represents another step in building Suntex into a stronger operating company,” said Javier Leal, CEO of Suntex Enterprises. “Deep South Electrical Contractors and GoldenEra Development bring established operations and ongoing project activity. Bringing these businesses under the Suntex umbrella allows us to continue expanding our operational platform and scale.” The execution of the Letter of Intent reflects the parties’ commitment to move forward with definitive agreements and finalize the transaction following customary due diligence and closing conditions. Full terms of the transaction, including the structure of the acquisition, will be announced once definitive agreements are finalized. About Suntex Enterprises, Inc. Suntex Enterprises, Inc. (OTC: SNTX) is focused on building and acquiring operating businesses across infrastructure, construction services, and asset-backed development opportunities. The Company’s strategy centers on expanding revenue-generating operations while strengthening its operational foundation for long-term growth. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements reflect current expectations regarding future events and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied. Suntex Enterprises undertakes no obligation to update forward-looking statements except as required by law. MEDIA CONTACT JA Development & Construction Media Relations [email protected] SOCIAL X: @SuntexEnt25 \| @JA_Development InvestorWire Service Contact: IBN Austin, Texas www.InvestorBrandNetwork.com 512.354.7000 Office [email protected]
	2026-03-05 20:06 6d ago	2026-03-05 14:50 6d ago	Tevogen Advances Generics Strategy, Signs Letter of Intent to Evaluate Potential Acquisition of Apozeal Pharmaceutical	stocknewsapi	TVGN
WARREN, N.J., March 05, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced that it has entered into a signed, non-exclusive, non-binding Letter of Intent (“LoI”) to evaluate a potential transaction with Apozeal Pharmaceutical Inc. (“Apozeal”), a pharmaceutical company focused on the development and manufacturing of high-quality, cost-effective medicines. The proposed transaction represents a strategic step in advancing Tevogen Generics, established to support domestic pharmaceutical manufacturing and enhance affordability and national supply chain resilience. If consummated, the potential acquisition of Apozeal could provide Tevogen with an established generics platform, including: 11 FDA-approved Abbreviated New Drug Application (ANDA) products for the U.S. marketMultiple ANDAs currently filed with the U.S. Food and Drug Administration awaiting approvalAdditional generic products in development Dr. Ryan Saadi, Founder and Chief Executive Officer of Tevogen, stated, “Tevogen Generics was launched with the objective of supporting pharmaceutical affordability and domestic manufacturing in the United States. The potential acquisition of Apozeal represents a meaningful step toward that strategy. With FDA-approved ANDA assets and a growing development pipeline, Apozeal could provide a foundation for building a revenue-generating generics business and could support Tevogen’s broader plan to expand U.S.-based pharmaceutical manufacturing.” The proposed transaction remains subject to, among other things, completion of due diligence, negotiation and execution of definitive documentation, required approvals, and satisfaction of customary closing conditions. Tevogen is also actively considering other transactions with a focus on life sciences-related businesses; however, there can be no assurance that any such transaction will be consummated. About Tevogen Tevogen is a socially integrated healthcare enterprise built on the principles of affordability, efficiency, and scientific rigor. The company leverages artificial intelligence and precision T cell therapy platforms, a patient-first and cost-disciplined operating model, and engagements with global technology leaders to support the development of advanced, life-saving therapies across multiple therapeutic areas and scalable solutions for the broader healthcare system. Tevogen Bio, the company’s lead initiative, has completed a proof-of-concept clinical trial demonstrating the potential of its single-HLA-restricted, genetically unmodified allogeneic T cells. Tevogen Bio’s pipeline spans virology, oncology, and neurology, with programs built on the company’s proprietary ExacTcell™ platform. Tevogen.AI is designed to transform drug development by accelerating target detection, helping reduce failure rates, and supporting optimized clinical trial design through proprietary predictive technologies. The platform utilizes cloud and data services from leading technology providers, including Microsoft and Databricks, to advance its long-term ambition to predict the proteome for any given protein–HLA combination, enabling rapid and cost-efficient therapeutic discovery. Tevogen is exploring future strategic initiatives that may include domestic generics, biosimilars, medical devices, and innovative insurance solutions for healthcare providers. Together, these programs reflect Tevogen’s mission to advance sustainable innovation and broaden patient access through a faster, more efficient, and more equitable healthcare model. Forward Looking Statements This press release contains certain forward-looking statements, including without limitation statements relating to: the potential transaction with Apozeal and the potential benefits of the transaction; Tevogen’s plans for its research and manufacturing capabilities; expectations regarding future growth; expectations regarding the healthcare and biopharmaceutical industries; and Tevogen’s development of, the potential benefits of, and patient access to its product candidates for the treatment of infectious diseases and cancer. Forward-looking statements can sometimes be identified by words such as “may,” “could,” “would,” “expect,” “anticipate,” “possible,” “potential,” “goal,” “opportunity,” “project,” “believe,” “future,” and similar words and expressions or their opposites. These statements are based on management’s expectations, assumptions, estimates, projections and beliefs as of the date of this press release and are subject to a number of factors that involve known and unknown risks, delays, uncertainties and other factors not under the company’s control that may cause actual results, performance or achievements of the company to be materially different from the results, performance or other expectations expressed or implied by these forward-looking statements. Factors that could cause actual results, performance, or achievements to differ from those expressed or implied by forward-looking statements include, but are not limited to: risks inherent in diligence and negotiation of the proposed transaction with Apozeal; the risk that the transaction with Apozeal may not be consummated on favorable terms or at all; the risk that the expected benefits of the transaction with Apozeal may not be realized on a timely basis or at all; changes in the markets in which Tevogen competes, including with respect to its competitive landscape, technology evolution, or regulatory changes; changes in domestic and global general economic conditions; the risk that Tevogen may not be able to execute its growth strategies or may experience difficulties in managing its growth and expanding operations; the risk that Tevogen may not be able to develop and maintain effective internal controls; the failure to achieve Tevogen’s commercialization and development plans and identify and realize additional opportunities, which may be affected by, among other things, competition, the ability of Tevogen to grow and manage growth economically and hire and retain key employees; the risk that Tevogen may fail to keep pace with rapid technological developments to provide new and innovative products and services or make substantial investments in unsuccessful new products and services; that Tevogen will need to raise additional capital to fully realize its business plans; risks related to the ability to develop, license or acquire new therapeutics; the risk of regulatory lawsuits or proceedings relating to Tevogen’s business; uncertainties inherent in the execution, cost, and completion of preclinical studies and clinical trials; risks related to regulatory review, approval and commercial development; risks associated with intellectual property protection; Tevogen’s limited operating history; and those factors discussed or incorporated by reference in Tevogen’s most recent Annual Report on Form 10-K and subsequent filings with the SEC. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Tevogen undertakes no obligation to update any forward-looking statements, except as required by applicable law. Contacts Tevogen Bio Communications T: 1 877 TEVOGEN, Ext 701 [email protected]
	2026-03-05 20:06 6d ago	2026-03-05 14:53 6d ago	Buy the Dip on This Bank Stock, Says Long-Term Signal	stocknewsapi	MS
$40 Gets You 4 High-Conviction Trades. Let's Go. We just booked back-to-back double-digit gains on Celsius and Palantir in Trade of the Week, and we’re eyeing even bigger wins! Every week starts with a fully defined options trade straight from the desk Schaeffer’s Senior V.P. of Research, Todd Salamone, backed by 30+ years of proven market experience and disciplined risk management. Right now, you can get 4 total trades over the next 4 weeks for $40 – just $10 per trade. 👉 Sign Up Now to Receive Your First Trade!
	2026-03-05 20:06 6d ago	2026-03-05 14:54 6d ago	$DSGR: Distribution Solutions Group Investigated for Securities Fraud; Block & Leviton Encourages Investors Who Have Lost Money to Contact the Firm	stocknewsapi	DSGR
BOSTON, March 05, 2026 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Distribution Solutions Group, Inc. (Nasdaq: DSGR) for potential securities law violations. Investors who have lost money in their Distribution Solutions Group investment should contact the firm to learn more about how they might recover those losses. For more details, visit https://blockleviton.com/cases/dsgr. What is this all about? Shares of Distribution Solutions Group fell over 25% on March 5, 2026, after the company reported Q4 2025 results. On their Q4 earnings call, CEO Bryan King stated that the company had “navigated challenging headwinds in 2025…including those driven by fluid tariffs.” However, when asked whether the company felt like it had its “arms around” tariffs just months earlier at a November 18, 2025, conference, CFO Ron Knutson responded: “Yes, yes, yes, we can. We can plan around it,” and added that “we [the company] feel like we've been in a pretty good place around the tariﬀ side.” Block & Leviton is investigating. Who is eligible? Anyone who purchased Distribution Solutions Group common stock and has seen their shares fall may be eligible, whether or not they have sold their investment. Investors should contact Block & Leviton to learn more. What is Block & Leviton doing? Block & Leviton is investigating whether the Company committed securities law violations and may file an action to attempt to recover losses on behalf of investors who have lost money. What should you do next? If you've lost money on your investment, you should contact Block & Leviton to learn more via our case website, by email at [email protected], or by phone at (888) 256-2510. Whistleblower? If you have non-public information about Distribution Solutions Group, you should consider assisting in our investigation or working with our attorneys to file a report with the Securities Exchange Commission under their whistleblower program. Whistleblowers who provide original information to the SEC may receive rewards of up to 30% of any successful recovery. For more information, contact Block & Leviton at [email protected] or by phone at (888) 256-2510. Why should you contact Block & Leviton? Block & Leviton is widely regarded as one of the leading securities class action firms in the country. Our attorneys have recovered billions of dollars for defrauded investors and are dedicated to obtaining significant recoveries on behalf of our clients through active litigation in the federal courts across the country. Many of the nation's top institutional investors hire us to represent their interests. You can learn more about us at our website www.blockleviton.com, call (888) 256-2510 or email [email protected] with any questions. This notice may constitute attorney advertising. CONTACT: BLOCK & LEVITON LLP 260 Franklin St., Suite 1860 Boston, MA 02110 Phone: (888) 256-2510 Email: [email protected]
	2026-03-05 20:06 6d ago	2026-03-05 14:55 6d ago	Robbins LLP Urges KD Stockholders Who Lost Money Investing in Kyndryl Holdings, Inc. to Contact the Firm for Information About Leading the Class Action	stocknewsapi	KD
SAN DIEGO, March 05, 2026 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Kyndryl Holdings, Inc. (NYSE: KD) securities between August 7, 2024 and February 9, 2026. Kyndryl describes itself as a “technology services company, which engages in the provision of infrastructure services.” For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. What is the class period? August 7, 2024 – February 9, 2026 What are the allegations? Robbins LLP is Investigating Allegations that Kyndryl Holdings, Inc. (KD) Materially Misstated its Financial Statements According to the complaint, during the class period defendants failed to disclose that: (1) Kyndryl’s financial statements issued during the class period were materially misstated; (2) Kyndryl lacked adequate internal controls and at times materially understated issues with its internal controls; and (3) as a result, Kyndryl would be unable to timely file its Quarterly Report on Form 10-Q for the quarter ended December 31, 2025. Plaintiff alleges that on February 9, 2026, Kyndryl filed with the SEC a Notification of Late Filing on Form 12b-5 announcing it would be unable to file its Quarterly Report on Form 10-Q for the quarter ended December 31, 2025 within the necessary time. The late filing notice also revealed the existence of an investigation by the SEC into the Company’s financial reporting and that the Company's Chief Financial Officer and General Counsel departed their positions, and the Senior V.P. and Global Controller assumed a different role. On this news, Kyndryl’s stock price fell $12.90 per share, or 55%, to close at $10.59 on February 9, 2026. What can shareholders do now? You may be eligible to participate in the class action against Kyndryl Holdings, Inc. Shareholders who wish to serve as lead plaintiff for the class must submit their papers to the court by April 13, 2026. The lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here. All representation is on a contingency fee basis. Shareholders pay no fees or expenses. About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. To be notified if a class action against Kyndryl Holdings, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today. Attorney Advertising. Past results do not guarantee a similar outcome.
	2026-03-05 20:06 6d ago	2026-03-05 14:55 6d ago	Impala Platinum Holdings Limited (IMPUY) Q2 2026 Earnings Call Transcript	stocknewsapi	IMPUY
Impala Platinum Holdings Limited (IMPUY) Q2 2026 Earnings Call March 5, 2026 4:30 AM EST Company Participants Nicolaas Muller - CEO & Executive Director Patrick Morutlwa - Group Chief Operating Officer Meroonisha Kerber - CFO, Debt Officer & Executive Director Johan Theron - Group Executive of Corporate Affairs Adelle Coetzee Moses Motlhageng - Chief Executive of Impala Rustenburg & CEO of Rustenburg Operations Sifiso Sibiya - Group Executive of Refining & Marketing Kirthanya Pillay - Group Executive of Corporate Development Conference Call Participants Christopher Nicholson - Morgan Stanley, Research Division Gerhard Engelbrecht - Absa Bank Limited, Research Division Arnold Van Graan - Nedbank Corporate and Investment Bank, Research Division Nkateko Mathonsi - Investec Bank Limited (SA), Research Division Presentation Nicolaas Muller CEO & Executive Director Good morning to everyone. Welcome here to all those present, the investment community, our own Implats people and for everyone who's dialed in as well, welcome. Always an honor to represent a very talented Implats team. Extraordinary times that we are living in. We had a presentation from one of the consulting firms the other day, and it was very clear that we are going through a shift in global order. It's a new era that is being introduced. We're seeing changes in international relationships, institutions, NATO, trade paths are changing, supply chains are changing. The move from globalization to multipolarity is accelerating. We just recently this weekend seen a new event unfold in the Middle East. And so all of this creates a number of consequences, one of which is uncertainty in future supply, particularly in natural resources and in our case, critical minerals and metals. And critical can be defined in many ways. But one is, if it's used in critical industries like in Europe, the auto industry is a very important employer. It affects politics. And so without our metals, there is a risk for the industry. But

Showing 3,001–3,050 of 82,499 articles